<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Benzodiazepine dependence - Wikipedia, the free encyclopedia</title>
<meta name="generator" content="MediaWiki 1.26wmf13" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Benzodiazepine_dependence" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="alternate" hreflang="x-default" href="/wiki/Benzodiazepine_dependence" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Benzodiazepine_dependence" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cmediawiki.ui.button%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: global:resourceloader:filter:minify-css:7:de1ab5287c9076b96eedd3f97a84a7b6 */</style>
<script src="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Benzodiazepine_dependence","wgTitle":"Benzodiazepine dependence","wgCurRevisionId":667301294,"wgRevisionId":667301294,"wgArticleId":20767273,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["CS1 Dutch-language sources (nl)","Pages containing cite templates with deprecated parameters","CS1 Spanish-language sources (es)","CS1 French-language sources (fr)","CS1 Japanese-language sources (ja)","CS1 German-language sources (de)","Wikipedia introduction cleanup from February 2015","All pages needing cleanup","Articles covered by WikiProject Wikify from February 2015","All articles covered by WikiProject Wikify","Articles with contributors link","All accuracy disputes","Articles with disputed statements from December 2011","Articles with DMOZ links","Articles that use a Medicine navs subtemplate","Pharmacology","Substance dependence","Syndromes","Benzodiazepines"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Benzodiazepine_dependence","wgRelevantArticleId":20767273,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wikilove-recipient":"","wikilove-anon":0,"wgPoweredByHHVM":true,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgGatherShouldShowTutorial":true,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Benzodiazepine_a.svg/88px-Benzodiazepine_a.svg.png","wgULSAcceptLanguageList":["en-us","en"],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q380409"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});
/* cache key: global:resourceloader:filter:minify-js:7:b2706269305541eba923c165462b22c4 */
}</script>
<script>if(window.mw){
mw.loader.implement("user.tokens",function($,jQuery){mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\"});});
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","mmv.head","ext.imageMetrics.head","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.26wmf13/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Benzodiazepine_dependence skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Benzodiazepine dependence</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="metadata plainlinks ambox ambox-style ambox-lead_too_long" role="presentation">
<tr>
<td class="mbox-image">
<div style="width:52px"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png" width="40" height="40" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/60px-Edit-clear.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/80px-Edit-clear.svg.png 2x" data-file-width="48" data-file-height="48" /></div>
</td>
<td class="mbox-text"><span class="mbox-text-span">This article's <b><a href="/wiki/Wikipedia:LEAD" title="Wikipedia:LEAD" class="mw-redirect">introduction</a> may be too long for the overall article length</b>. <span class="hide-when-compact">Please help by moving some material from it into the body of the article. For more information please read the <a href="/wiki/Wikipedia:Layout_guide" title="Wikipedia:Layout guide" class="mw-redirect">layout guide</a> and Wikipedia's <a href="/wiki/Wikipedia:LEADLENGTH" title="Wikipedia:LEADLENGTH" class="mw-redirect">lead section guidelines</a>.</span> <small><i>(February 2015)</i></small></span></td>
</tr>
</table>
<table class="infobox" style="width:22em">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey">Benzodiazepine dependence</th>
</tr>
<tr>
<th colspan="2" style="text-align:center">Classification and external resources</th>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2015/en#/F13">F13</a>.2</td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9-CM</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=304.1">304.1</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb29548.htm">29548</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/003578.htm">003578</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/Bztox/topic813255.htm">Bztox/813255</a></td>
</tr>
</table>
<p><b>Benzodiazepine dependence</b> or <b>benzodiazepine addiction</b> is when one has developed one or more of either <a href="/wiki/Drug_tolerance" title="Drug tolerance">tolerance</a>, <a href="/wiki/Benzodiazepine_withdrawal_syndrome" title="Benzodiazepine withdrawal syndrome">withdrawal symptoms</a>, drug seeking behaviors, such as continued use despite harmful effects, and maladaptive pattern of substance use, according to the <a href="/wiki/DSM-IV" title="DSM-IV" class="mw-redirect">DSM-IV</a>. In the case of <a href="/wiki/Benzodiazepine" title="Benzodiazepine">benzodiazepine</a> dependence, however, the continued use seems to be associated with the avoidance of unpleasant withdrawal reaction rather than from the pleasurable effects of the drug.<sup id="cite_ref-pmid1679388_1-0" class="reference"><a href="#cite_note-pmid1679388-1"><span>[</span>1<span>]</span></a></sup> Benzodiazepine dependence develops with long-term use, even at low therapeutic doses,<sup id="cite_ref-Nutt_2-0" class="reference"><a href="#cite_note-Nutt-2"><span>[</span>2<span>]</span></a></sup> without the described dependence behavior.<sup id="cite_ref-Uzun-2010_3-0" class="reference"><a href="#cite_note-Uzun-2010-3"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-4" class="reference"><a href="#cite_note-4"><span>[</span>4<span>]</span></a></sup></p>
<p>Addiction, or what is sometimes referred to as psychological dependence, includes people misusing and/or craving the drug not to relieve withdrawal symptoms, but to experience its euphoric and/or intoxicating effects. It is important to distinguish between <a href="/wiki/Substance_use_disorder" title="Substance use disorder">addiction</a> and <a href="/wiki/Drug_abuse" title="Drug abuse" class="mw-redirect">drug abuse</a> of benzodiazepines and normal <a href="/wiki/Physical_dependence" title="Physical dependence">physical dependence</a> on benzodiazepines. The increased <a href="/wiki/GABAA_receptor" title="GABAA receptor">GABA<sub>A</sub> inhibition</a> caused by benzodiazepines is counteracted by the body's development of <a href="/wiki/Drug_tolerance" title="Drug tolerance">tolerance</a> to the drug's effects; the development of tolerance occurs as a result of neuroadaptations, which result in decreased GABA inhibition and increased excitability of the glutamate system; these adaptations occur as a result of the body trying to overcome the central nervous system depressant effects of the drug to restore <a href="/wiki/Homeostasis" title="Homeostasis">homeostasis</a>. When benzodiazepines are stopped, these neuroadaptations are "unmasked" leading to hyper-excitability of the nervous system and the appearance of withdrawal symptoms.<sup id="cite_ref-Allison-2003_5-0" class="reference"><a href="#cite_note-Allison-2003-5"><span>[</span>5<span>]</span></a></sup></p>
<p>Therapeutic dose dependence is the largest category of people dependent on benzodiazepines. These individuals typically do not escalate their doses to high levels or abuse their medication. Smaller groups include patients escalating their dosage to higher levels and drug misusers as well. It is unclear exactly how many people illicitly abuse benzodiazepines. Tolerance develops within days or weeks to the anticonvulsant, hypnotic muscle relaxant and after 4 months there is little evidence that benzodiazepines retain their anxiolytic properties. Some authors, however, disagree and feel that benzodiazepines retain their anxiolytic properties.<sup id="cite_ref-asapdacg_6-0" class="reference"><a href="#cite_note-asapdacg-6"><span>[</span>6<span>]</span></a></sup> Long-term benzodiazepine treatment may remain necessary in certain clinical conditions.<sup id="cite_ref-current_use_2009_7-0" class="reference"><a href="#cite_note-current_use_2009-7"><span>[</span>7<span>]</span></a></sup></p>
<p>Dependence and misuse of benzodiazepines have been of concern since 2002. Based on findings in the US from the Treatment Episode Data Set (TEDS), an annual compilation of patient characteristics in substance abuse treatment facilities in the United States, admissions due to "primary tranquilizer" (including, but not limited to, benzodiazepine-type) drug use increased 79% from 1992 to 2002. Thus, the DAWN and TEDS data sets demonstrate clearly that the misuse of these sedative/hypnotics is on the rise, and cause for concern.<sup id="cite_ref-pmid18295321_8-0" class="reference"><a href="#cite_note-pmid18295321-8"><span>[</span>8<span>]</span></a></sup></p>
<p>Numbers of benzodiazepine prescriptions have been declining, due primarily to concerns of dependence. In the short term, benzodiazepines can be effective drugs for acute anxiety or insomnia. With longer-term use, other therapies, both pharmacological and psychotherapeutic, become more effective. This is in part due to the greater effectiveness over time of other forms of therapy, and also due to the eventual development of pharmacological benzodiazepine tolerance.<sup id="cite_ref-sbtp_9-0" class="reference"><a href="#cite_note-sbtp-9"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-pmid10779253_10-0" class="reference"><a href="#cite_note-pmid10779253-10"><span>[</span>10<span>]</span></a></sup></p>
<table class="vertical-navbox nowraplinks plainlist" style="float:right;clear:right;width:22.0em;margin:0 0 1.0em 1.0em;background:#f9f9f9;border:1px solid #aaa;padding:0.2em;border-spacing:0.4em 0;text-align:center;line-height:1.4em;font-size:88%">
<tr>
<th style="padding:0.2em 0.4em 0.2em;font-size:145%;line-height:1.2em;background: #CCF"><a href="/wiki/Benzodiazepine" title="Benzodiazepine">Benzodiazepines</a></th>
</tr>
<tr>
<td style="padding:0.2em 0 0.4em"><a href="/wiki/File:Benzodiazepine_a.svg" class="image"><img alt="Chemical structure diagram of a benzene ring fused to a diazepine ring. Another benzene ring is attached to the bottom of the diazepine ring via a single line. Attached to the first benzene ring is a side chain labeled R7; to the second, a side chain labeled R2'; and attached to the diazepine ring, two side chains labeled R1 and R2." src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Benzodiazepine_a.svg/160px-Benzodiazepine_a.svg.png" width="160" height="182" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Benzodiazepine_a.svg/240px-Benzodiazepine_a.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Benzodiazepine_a.svg/320px-Benzodiazepine_a.svg.png 2x" data-file-width="512" data-file-height="582" /></a>
<div style="padding-top:0.2em;line-height:1.2em">The core structure of benzodiazepines. "R" labels denote common locations of <a href="/wiki/Side_chain" title="Side chain">side chains</a>, which give different benzodiazepines their unique properties.</div>
</td>
</tr>
<tr>
<td style="padding:0 0.1em 0.4em">
<ul>
<li><a href="/wiki/Benzodiazepine" title="Benzodiazepine">Benzodiazepine</a></li>
<li><a href="/wiki/List_of_benzodiazepines" title="List of benzodiazepines">List of benzodiazepines</a></li>
<li><a href="/wiki/Benzodiazepine_overdose" title="Benzodiazepine overdose">Benzodiazepine overdose</a></li>
<li><strong class="selflink">Benzodiazepine dependence</strong></li>
<li><a href="/wiki/Benzodiazepine_misuse" title="Benzodiazepine misuse">Benzodiazepine misuse</a></li>
<li><a href="/wiki/Benzodiazepine_withdrawal_syndrome" title="Benzodiazepine withdrawal syndrome">Benzodiazepine withdrawal syndrome</a></li>
<li><a href="/wiki/Effects_of_long-term_benzodiazepine_use" title="Effects of long-term benzodiazepine use">Effects of long-term benzodiazepine use</a></li>
</ul>
</td>
</tr>
<tr>
<td style="text-align:right;font-size:115%">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Benzos" title="Template:Benzos"><span title="View this template">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Benzos" title="Template talk:Benzos"><span title="Discuss this template">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Benzos&amp;action=edit"><span title="Edit this template">e</span></a></li>
</ul>
</div>
</td>
</tr>
</table>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Definition"><span class="tocnumber">1</span> <span class="toctext">Definition</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Signs_and_symptoms"><span class="tocnumber">2</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Cause"><span class="tocnumber">3</span> <span class="toctext">Cause</span></a>
<ul>
<li class="toclevel-2 tocsection-4"><a href="#Risk_factors"><span class="tocnumber">3.1</span> <span class="toctext">Risk factors</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-5"><a href="#Mechanism"><span class="tocnumber">4</span> <span class="toctext">Mechanism</span></a>
<ul>
<li class="toclevel-2 tocsection-6"><a href="#Tolerance_and_physical_dependence"><span class="tocnumber">4.1</span> <span class="toctext">Tolerance and physical dependence</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Cross_tolerance"><span class="tocnumber">4.2</span> <span class="toctext">Cross tolerance</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Physiology_of_withdrawal"><span class="tocnumber">4.3</span> <span class="toctext">Physiology of withdrawal</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Withdrawal"><span class="tocnumber">4.4</span> <span class="toctext">Withdrawal</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Prevention"><span class="tocnumber">5</span> <span class="toctext">Prevention</span></a>
<ul>
<li class="toclevel-2 tocsection-11"><a href="#The_Committee_on_the_Review_of_Medicines_.28UK.29"><span class="tocnumber">5.1</span> <span class="toctext">The Committee on the Review of Medicines (UK)</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Diagnosis"><span class="tocnumber">6</span> <span class="toctext">Diagnosis</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#In_the_elderly"><span class="tocnumber">7</span> <span class="toctext">In the elderly</span></a></li>
<li class="toclevel-1 tocsection-14"><a href="#Treatment_and_prevention"><span class="tocnumber">8</span> <span class="toctext">Treatment and prevention</span></a>
<ul>
<li class="toclevel-2 tocsection-15"><a href="#Flumazenil_as_treatment_for_benzodiazepine_dependence"><span class="tocnumber">8.1</span> <span class="toctext">Flumazenil as treatment for benzodiazepine dependence</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Letter_to_patients"><span class="tocnumber">8.2</span> <span class="toctext">Letter to patients</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Pharmacist_intervention_programs"><span class="tocnumber">8.3</span> <span class="toctext">Pharmacist intervention programs</span></a></li>
<li class="toclevel-2 tocsection-18"><a href="#Cognitive_behavioral_therapy"><span class="tocnumber">8.4</span> <span class="toctext">Cognitive behavioral therapy</span></a></li>
<li class="toclevel-2 tocsection-19"><a href="#Legal_implications"><span class="tocnumber">8.5</span> <span class="toctext">Legal implications</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-20"><a href="#Epidemiology"><span class="tocnumber">9</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-21"><a href="#History"><span class="tocnumber">10</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-22"><a href="#Misuse_and_addiction"><span class="tocnumber">11</span> <span class="toctext">Misuse and addiction</span></a></li>
<li class="toclevel-1 tocsection-23"><a href="#See_also"><span class="tocnumber">12</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-24"><a href="#References"><span class="tocnumber">13</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-25"><a href="#External_links"><span class="tocnumber">14</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Definition">Definition</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=1" title="Edit section: Definition">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Benzodiazepine dependence is the condition resulting from repeated use of benzodiazepine drugs. It can include both a <a href="/wiki/Physical_dependence" title="Physical dependence">physical dependence</a> as well as a <a href="/wiki/Psychological_dependence" title="Psychological dependence">psychological dependence</a> and is typified by a withdrawal syndrome upon a fall in blood plasma levels of benzodiazepines, e.g., during dose reduction or abrupt withdrawal.<sup id="cite_ref-Authier-2009_11-0" class="reference"><a href="#cite_note-Authier-2009-11"><span>[</span>11<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=2" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="hatnote">See also: <a href="/wiki/Benzodiazepine_withdrawal_syndrome#Signs_and_symptoms" title="Benzodiazepine withdrawal syndrome">Benzodiazepine withdrawal syndrome § Signs and symptoms</a></div>
<p>The signs and symptoms of benzodiazepine dependence include feeling unable to cope without the drug, unsuccessful attempts to cut down or stop benzodiazepine use, tolerance to the effects of benzodiazepines, and withdrawal symptoms when not taking the drug. Some withdrawal symptoms that may appear include <a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, <a href="/wiki/Depressed_mood" title="Depressed mood" class="mw-redirect">depressed mood</a>, <a href="/wiki/Depersonalisation" title="Depersonalisation" class="mw-redirect">depersonalisation</a>, <a href="/wiki/Derealisation" title="Derealisation" class="mw-redirect">derealisation</a>, <a href="/wiki/Sleep_disturbance" title="Sleep disturbance" class="mw-redirect">sleep disturbance</a>, hypersensitivity to touch and pain, <a href="/wiki/Tremor" title="Tremor">tremor</a>, <a href="/wiki/Shakiness" title="Shakiness" class="mw-redirect">shakiness</a>, muscular aches, pains, twitches, and headache.<sup id="cite_ref-Khong-2004_12-0" class="reference"><a href="#cite_note-Khong-2004-12"><span>[</span>12<span>]</span></a></sup> Benzodiazepine dependence and withdrawal have been associated with suicide and self-harming behaviors, especially in young people. The <a href="/wiki/Department_of_Health_(United_Kingdom)" title="Department of Health (United Kingdom)">Department of Health</a> substance misuse guidelines recommend monitoring for mood disorder in those dependent on or withdrawing from benzodiazepines.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span>[</span>13<span>]</span></a></sup></p>
<p>Benzodiazepine dependence is a frequent complication for those prescribed for or using for longer than four weeks, with physical dependence and withdrawal symptoms being the most common problem, but also occasionally drug-seeking behavior. Withdrawal symptoms include anxiety, perceptual disturbances, distortion of all the senses, dysphoria, and, in rare cases, psychosis and epileptic seizures.<sup id="cite_ref-Marriott-1993_14-0" class="reference"><a href="#cite_note-Marriott-1993-14"><span>[</span>14<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Cause">Cause</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=3" title="Edit section: Cause">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Tolerance occurs to the muscle-relaxant, anticonvulsant, and sleep-inducing effects of benzodiazepines, and upon cessation a benzodiazepine withdrawal syndrome occurs. This can lead to benzodiazepines being taken for longer than originally intended, as people continue to take the drugs over a long period of time to suppress withdrawal symptoms. Some people abuse benzodiazepines at very high doses and devote a lot of time to doing so, satisfying the diagnostic criteria in DSM IV for substance abuse and dependence. Another group of people include those on low to moderate therapeutic doses of benzodiazepines who do not abuse their benzodiazepines but develop a tolerance and benzodiazepine dependence.<sup id="cite_ref-Allison-2003_5-1" class="reference"><a href="#cite_note-Allison-2003-5"><span>[</span>5<span>]</span></a></sup> A considerable number of individuals using benzodiazepines for insomnia escalate their dosage, sometimes above therapeutically-prescribed dose levels. Tolerance to the anxiolytic effect of benzodiazepines has been clearly demonstrated in rats. In humans, there is little evidence that benzodiazepines retain their anti-anxiety effects beyond four months of continuous treatment; there is evidence that suggests that long-term use of benzodiazepines may actually worsen anxiety, which in turn may lead to dosage escalation, with one study finding 25% of patients escalated their dosage. Some authors, however, consider benzodiazepines to be effective long-term; however, it is more likely that the drugs are acting to prevent rebound anxiety withdrawal effects.<sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Disputed_statement" title="Wikipedia:Disputed statement" class="mw-redirect"><span title="The material near this tag is possibly inaccurate or nonfactual. (December 2011)">dubious</span></a> <span class="metadata">– <a href="/wiki/Talk:Benzodiazepine_dependence#Dubious" title="Talk:Benzodiazepine dependence">discuss</a></span></i>]</sup> Tolerance to the anticonvulsant and muscle-relaxing effects of benzodiazepines occurs within a few weeks in most patients.<sup id="cite_ref-asapdacg_6-1" class="reference"><a href="#cite_note-asapdacg-6"><span>[</span>6<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Risk_factors">Risk factors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=4" title="Edit section: Risk factors">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The risk factors for benzodiazepine dependence are long-term use beyond four weeks, use of high doses, use of potent short-acting benzodiazepines, dependent personalities, and proclivity for drug abuse.<sup id="cite_ref-Marriott-1993_14-1" class="reference"><a href="#cite_note-Marriott-1993-14"><span>[</span>14<span>]</span></a></sup> Use of short-acting benzodiazepines leads to repeated withdrawal effects that are alleviated by the next dose, which reinforce in the individual the dependence.<sup id="cite_ref-Khong-2004_12-1" class="reference"><a href="#cite_note-Khong-2004-12"><span>[</span>12<span>]</span></a></sup> A physical dependence develops more quickly with higher potency benzodiazepines such as <a href="/wiki/Alprazolam" title="Alprazolam">alprazolam</a> (Xanax) than with lower potency benzodiazepines such as <a href="/wiki/Chlordiazepoxide" title="Chlordiazepoxide">chlordiazepoxide</a> (Librium).<sup id="cite_ref-pmid10779253_10-1" class="reference"><a href="#cite_note-pmid10779253-10"><span>[</span>10<span>]</span></a></sup></p>
<p>Symptom severity is worse with the use of high doses, or with benzodiazepines of high potency or short half-life. Other <a href="/wiki/Cross-tolerant" title="Cross-tolerant" class="mw-redirect">cross-tolerant</a> sedative hypnotics, such as <a href="/wiki/Barbiturates" title="Barbiturates" class="mw-redirect">barbiturates</a> or <a href="/wiki/Ethanol" title="Ethanol">alcohol</a>, increase the risk of benzodiazepine dependence.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span>[</span>15<span>]</span></a></sup> Similar to opioids' use for pain, therapeutic use of benzodiazepines rarely leads to substance abuse.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Mechanism">Mechanism</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=5" title="Edit section: Mechanism">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Tolerance_and_physical_dependence">Tolerance and physical dependence</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=6" title="Edit section: Tolerance and physical dependence">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">See also: <a href="/wiki/Kindling_(substance_withdrawal)" title="Kindling (substance withdrawal)" class="mw-redirect">Kindling (substance withdrawal)</a></div>
<p>Tolerance develops rapidly to the sleep-inducing effects of benzodiazepine. The anticonvulsant and muscle-relaxant effects last for a few weeks before tolerance develops in most individuals. <a href="/wiki/Drug_tolerance" title="Drug tolerance">Tolerance</a> results in a desensitization of GABA receptors and an increased sensitization of the excitatory neurotransmitter system, <a href="/wiki/Glutamate" title="Glutamate" class="mw-redirect">glutamate</a> such as <a href="/wiki/NMDA" title="NMDA" class="mw-redirect">NMDA</a> glutamate receptors. These changes occur as a result of the body trying to overcome the drug's effects. Other changes that occur are the reduction of the number of GABA receptors (<a href="/wiki/Internalization" title="Internalization">internalization</a>) as well as possibly long-term changes in <a href="/wiki/Gene_transcription" title="Gene transcription" class="mw-redirect">gene transcription</a> coding of brain cells. The differing speed at which tolerance occurs to the therapeutic effects of benzodiazepines can be explained by the speed of changes in the range of <a href="/wiki/Neurotransmitter_systems" title="Neurotransmitter systems" class="mw-redirect">neurotransmitter systems</a> and subsystems that are altered by chronic benzodiazepine use. The various neurotransmitter systems and subsystems may reverse tolerance at different speeds, thus explaining the prolonged nature of some withdrawal symptoms. As a result of a <a href="/wiki/Physical_dependence" title="Physical dependence">physical dependence</a> that develops due to tolerance, a characteristic <a href="/wiki/Benzodiazepine_withdrawal_syndrome" title="Benzodiazepine withdrawal syndrome">benzodiazepine withdrawal syndrome</a> often occurs after removal of the drug or a reduction in dosage.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17"><span>[</span>17<span>]</span></a></sup> Changes in the expression of <a href="/wiki/Neuropeptides" title="Neuropeptides" class="mw-redirect">neuropeptides</a> such as <a href="/wiki/Corticotropin-releasing_hormone" title="Corticotropin-releasing hormone">corticotropin-releasing hormone</a> and <a href="/wiki/Neuropeptide_Y" title="Neuropeptide Y">neuropeptide Y</a> may play a role in benzodiazepine dependence.<sup id="cite_ref-Heberlein_A_7.E2.80.9315_18-0" class="reference"><a href="#cite_note-Heberlein_A_7.E2.80.9315-18"><span>[</span>18<span>]</span></a></sup> Individuals taking daily benzodiazepine drugs have a reduced sensitivity to further additional doses of benzodiazepines.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19"><span>[</span>19<span>]</span></a></sup> Tolerance to benzodiazepines can be demonstrated by injecting diazepam into long-term users. In normal subjects, increases in growth hormone occurs, whereas, in benzodiazepine-tolerant individuals, this effect is blunted.<sup id="cite_ref-bdmrch2005_20-0" class="reference"><a href="#cite_note-bdmrch2005-20"><span>[</span>20<span>]</span></a></sup></p>
<p>Animal studies have shown that repeated withdrawal from benzodiazepines leads to increasingly severe withdrawal symptoms, including an increased risk of seizures; this phenomenon is known as <a href="/wiki/Kindling_(substance_withdrawal)" title="Kindling (substance withdrawal)" class="mw-redirect">kindling</a>. Kindling phenomena are well established for repeated ethanol (alcohol) withdrawal; alcohol has a very similar mechanism of tolerance and withdrawal to benzodiazepines, involving the GABAa, NMDA, and AMPA receptors.<sup id="cite_ref-Allison-2003_5-2" class="reference"><a href="#cite_note-Allison-2003-5"><span>[</span>5<span>]</span></a></sup></p>
<p>The shift of benzodiazepine receptors to an inverse agonist state after chronic treatment leads the brain to be more sensitive to excitatory drugs or stimuli. Excessive glutamate activity can result in <a href="/wiki/Excitotoxicity" title="Excitotoxicity">excitotoxicity</a>, which may result in <a href="/wiki/Neurodegeneration" title="Neurodegeneration">neurodegeneration</a>. The glutamate receptor subtype NMDA is well known for its role in causing excito-neurotoxicity. The glutamate receptor subtype AMPA is believed to play an important role in neuronal kindling as well as excitotoxicity during withdrawal from alcohol as well as benzodiazepines. It is highly possible that NMDA receptors are involved in the tolerance to some effects of benzodiazepines.<sup id="cite_ref-Allison-2003_5-3" class="reference"><a href="#cite_note-Allison-2003-5"><span>[</span>5<span>]</span></a></sup></p>
<p>Animal studies have found that glutamergic changes as a result of benzodiazepine use are responsible for a delayed withdrawal syndrome, which in mice peaks 3 days after cessation of benzodiazepines. This was demonstrated by the ability to avoid the withdrawal syndrome by the administration of AMPA antagonists. It is believed that different glutamate subreceptors, e.g., NMDA and AMPA, are responsible for different stages/time points of the withdrawal syndrome. NMDA receptors are upregulated in the brain as a result of benzodiazepine tolerance. AMPA receptors are also involved in benzodiazepine tolerance and withdrawal.<sup id="cite_ref-Allison-2003_5-4" class="reference"><a href="#cite_note-Allison-2003-5"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-Koff_JM.2C_Pritchard_GA.2C_Greenblatt_DJ.2C_Miller_LG_1997_217.E2.80.9327_21-0" class="reference"><a href="#cite_note-Koff_JM.2C_Pritchard_GA.2C_Greenblatt_DJ.2C_Miller_LG_1997_217.E2.80.9327-21"><span>[</span>21<span>]</span></a></sup><sup id="cite_ref-Koff_JM.2C_Pritchard_GA.2C_Greenblatt_DJ.2C_Miller_LG_1997_217.E2.80.9327_21-1" class="reference"><a href="#cite_note-Koff_JM.2C_Pritchard_GA.2C_Greenblatt_DJ.2C_Miller_LG_1997_217.E2.80.9327-21"><span>[</span>21<span>]</span></a></sup> A decrease in benzodiazepine binding sites in the brain may also occur as part of benzodiazepine tolerance.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span>[</span>22<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Cross_tolerance">Cross tolerance</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=7" title="Edit section: Cross tolerance">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Benzodiazepine" title="Benzodiazepine">Benzodiazepines</a> share a similar mechanism of action with various sedative compounds that act by enhancing the GABA<sub>A</sub> receptor. <i><a href="/wiki/Cross_tolerance" title="Cross tolerance" class="mw-redirect">Cross tolerance</a></i> means that one drug will alleviate the withdrawal effects of another. It also means that tolerance of one drug will result in tolerance of another similarly-acting drug. <a href="/wiki/Benzodiazepine" title="Benzodiazepine">Benzodiazepines</a> are often used for this reason to detoxify alcohol-dependent patients and can have life-saving properties in preventing and/or treating severe life-threatening withdrawal syndromes from alcohol, such as <a href="/wiki/Delirium_tremens" title="Delirium tremens">delirium tremens</a>. However, although benzodiazepines can be very useful in the acute <a href="/wiki/Alcohol_detoxification" title="Alcohol detoxification">detoxification</a> of alcoholics, benzodiazepines in themselves act as positive reinforcers in alcoholics, by increasing the desire for alcohol. Low doses of benzodiazepines were found to significantly increase the level of alcohol consumed in alcoholics.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span>[</span>23<span>]</span></a></sup> <a href="/wiki/Alcoholic" title="Alcoholic" class="mw-redirect">Alcoholics</a> dependent on benzodiazepines should not be abruptly withdrawn but be very slowly withdrawn from benzodiazepines, as over-rapid withdrawal is likely to produce severe anxiety or panic, which is well known for being a relapse risk factor in recovering alcoholics.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span>[</span>24<span>]</span></a></sup></p>
<p>There is cross tolerance between <a href="/wiki/Alcoholic_beverage" title="Alcoholic beverage">alcohol</a>, the <a href="/wiki/Benzodiazepines" title="Benzodiazepines" class="mw-redirect">benzodiazepines</a>, the <a href="/wiki/Barbiturate" title="Barbiturate">barbiturates</a>, the <a href="/wiki/Nonbenzodiazepine" title="Nonbenzodiazepine">nonbenzodiazepine</a> drugs, and <a href="/wiki/Corticosteroids" title="Corticosteroids" class="mw-redirect">corticosteroids</a>, which all act by enhancing the GABA<sub>A</sub> receptor's function via modulating the chloride ion channel function of the GABA<sub>A</sub> receptor.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-26" class="reference"><a href="#cite_note-26"><span>[</span>26<span>]</span></a></sup><sup id="cite_ref-27" class="reference"><a href="#cite_note-27"><span>[</span>27<span>]</span></a></sup><sup id="cite_ref-28" class="reference"><a href="#cite_note-28"><span>[</span>28<span>]</span></a></sup><sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span>[</span>29<span>]</span></a></sup></p>
<p><a href="/wiki/Neuroactive_steroids" title="Neuroactive steroids" class="mw-redirect">Neuroactive steroids</a>, e.g., <a href="/wiki/Progesterone" title="Progesterone">progesterone</a> and its active metabolite <a href="/wiki/Allopregnanolone" title="Allopregnanolone">allopregnanolone</a>, are positive modulators of the GABA<sub>A</sub> receptor and are cross tolerant with benzodiazepines.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30"><span>[</span>30<span>]</span></a></sup> The <a href="/wiki/Active_metabolite" title="Active metabolite">active metabolite</a> of progesterone has been found to enhance the binding of benzodiazepines to the benzodiazepine binding sites on the GABA<sub>A</sub> receptor.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span>[</span>31<span>]</span></a></sup> The cross-tolerance between GABA<sub>A</sub> receptor positive modulators occurs because of the similar mechanism of action and the subunit changes that occur from chronic use from one or more of these compounds in expressed receptor isoforms. Abrupt withdrawal from any of these compounds, e.g., <a href="/wiki/Barbiturates" title="Barbiturates" class="mw-redirect">barbiturates</a>, <a href="/wiki/Benzodiazepines" title="Benzodiazepines" class="mw-redirect">benzodiazepines</a>, alcohol, <a href="/wiki/Corticosteroids" title="Corticosteroids" class="mw-redirect">corticosteroids</a>, <a href="/wiki/Neuroactive_steroids" title="Neuroactive steroids" class="mw-redirect">neuroactive steroids</a>, and nonbenzodiazepines, precipitate similar withdrawal effects characterized by central nervous system hyper-excitability, resulting in symptoms such as increased seizure susceptibility and anxiety.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span>[</span>32<span>]</span></a></sup> While many of the neuroactive steroids do not produce full tolerance to their therapeutic effects, cross-tolerance to benzodiazepines still occurs as had been demonstrated between the neuroactive steroid <a href="/wiki/Ganaxolone" title="Ganaxolone">ganaxolone</a> and <a href="/wiki/Diazepam" title="Diazepam">diazepam</a>. Alterations of levels of neuroactive steroids in the body during the menstrual cycle, <a href="/wiki/Menopause" title="Menopause">menopause</a>, pregnancy, and stressful circumstances can lead to a reduction in the effectiveness of benzodiazepines and a reduced therapeutic effect. During withdrawal of neuroactive steroids, benzodiazepines become less effective.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span>[</span>33<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Physiology_of_withdrawal">Physiology of withdrawal</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=8" title="Edit section: Physiology of withdrawal">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Withdrawal_symptoms" title="Withdrawal symptoms" class="mw-redirect">Withdrawal symptoms</a> are a normal response in individuals having chronically used benzodiazepines, and an adverse effect and result of <a href="/wiki/Drug_tolerance" title="Drug tolerance">drug tolerance</a>. Symptoms typically emerge when dosage of the drug is reduced. <a href="/wiki/GABA" title="GABA" class="mw-redirect">GABA</a> is the second-most-common neurotransmitter in the <a href="/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a> (the most common being <a href="/wiki/Glutamate" title="Glutamate" class="mw-redirect">glutamate</a><sup id="cite_ref-pmid7568184_34-0" class="reference"><a href="#cite_note-pmid7568184-34"><span>[</span>34<span>]</span></a></sup><sup id="cite_ref-pmid17684524_35-0" class="reference"><a href="#cite_note-pmid17684524-35"><span>[</span>35<span>]</span></a></sup><sup id="cite_ref-36" class="reference"><a href="#cite_note-36"><span>[</span>36<span>]</span></a></sup>) and by far the most abundant inhibitory neurotransmitter; roughly one-quarter to one-third of synapses use GABA.<sup id="cite_ref-url_synapses_37-0" class="reference"><a href="#cite_note-url_synapses-37"><span>[</span>37<span>]</span></a></sup> The use of benzodiazepines has a profound effect on almost every aspect of <a href="/wiki/Brain" title="Brain">brain</a> and body function, either directly or indirectly.<sup id="cite_ref-ashman_38-0" class="reference"><a href="#cite_note-ashman-38"><span>[</span>38<span>]</span></a></sup></p>
<p>Benzodiazepines cause a decrease in <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a> (noradrenaline), <a href="/wiki/Serotonin" title="Serotonin">serotonin</a>, <a href="/wiki/Acetylcholine" title="Acetylcholine">acetylcholine</a>, and <a href="/wiki/Dopamine" title="Dopamine">dopamine</a>. These <a href="/wiki/Neurotransmitters" title="Neurotransmitters" class="mw-redirect">neurotransmitters</a> are needed for normal memory, mood, <a href="/wiki/Muscle_tone" title="Muscle tone">muscle tone</a> and coordination, emotional responses, <a href="/wiki/Endocrine" title="Endocrine" class="mw-redirect">endocrine</a> gland secretions, heart rate, and blood pressure control. With chronic benzodiazepine use, <a href="/wiki/Drug_tolerance" title="Drug tolerance">tolerance</a> develops rapidly to most of its effects, so that, when benzodiazepines are withdrawn, various <a href="/wiki/Neurotransmitter" title="Neurotransmitter">neurotransmitter</a> systems go into overdrive due to the lack of inhibitory <a href="/wiki/GABA" title="GABA" class="mw-redirect">GABA</a>-ergic activity. Withdrawal symptoms then emerge as a result, and persist until the nervous system physically reverses the adaptions (physical dependence) that have occurred in the CNS.<sup id="cite_ref-ashman_38-1" class="reference"><a href="#cite_note-ashman-38"><span>[</span>38<span>]</span></a></sup></p>
<p>Withdrawal symptoms typically consist of a mirror image of the drug's effects: Sedative effects and suppression of <a href="/wiki/Rapid_eye_movement_sleep" title="Rapid eye movement sleep">REM</a> and <a href="/wiki/Slow-wave_sleep" title="Slow-wave sleep">SWS</a> stages of sleep can be replaced by <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, <a href="/wiki/Nightmares" title="Nightmares" class="mw-redirect">nightmares</a>, and <a href="/wiki/Hypnogogic" title="Hypnogogic" class="mw-redirect">hypnogogic</a> hallucinations; its antianxiety effects are replaced with anxiety and panic; muscle-relaxant effects are replaced with muscular spasms or cramps; and <a href="/wiki/Anticonvulsant" title="Anticonvulsant">anticonvulsant</a> effects are replaced with seizures, especially in <a href="/wiki/Cold_turkey" title="Cold turkey">cold turkey</a> or overly-rapid withdrawal.<sup id="cite_ref-ashman_38-2" class="reference"><a href="#cite_note-ashman-38"><span>[</span>38<span>]</span></a></sup></p>
<p>Benzodiazepine withdrawal represents in part <a href="/wiki/Excitotoxicity" title="Excitotoxicity">excitotoxicity</a> to brain neurons.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39"><span>[</span>39<span>]</span></a></sup> <a href="/wiki/Rebound_activity" title="Rebound activity" class="mw-redirect">Rebound activity</a> of the <a href="/wiki/Hypothalamic-pituitary-adrenocortical_axis" title="Hypothalamic-pituitary-adrenocortical axis" class="mw-redirect">hypothalamic-pituitary-adrenocortical axis</a> also plays an important role in the severity of benzodiazepine withdrawal.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40"><span>[</span>40<span>]</span></a></sup> Tolerance and the resultant withdrawal syndrome may be due to alterations in gene expression, which results in long-term changes in the function of the GABAergic neuronal system.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41"><span>[</span>41<span>]</span></a></sup><sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span>[</span>42<span>]</span></a></sup></p>
<p>During withdrawal from full or partial agonists, changes occur in benzodiazepine receptor with upregulation of some receptor subtypes and downregulation of other receptor subtypes.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43"><span>[</span>43<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Withdrawal">Withdrawal</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=9" title="Edit section: Withdrawal">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">See also: <a href="/wiki/Benzodiazepine_withdrawal_syndrome" title="Benzodiazepine withdrawal syndrome">Benzodiazepine withdrawal syndrome</a></div>
<p><a href="/wiki/Effects_of_long-term_benzodiazepine_use" title="Effects of long-term benzodiazepine use">Long-term use of benzodiazepines</a> leads to increasing physical and mental health problems, and as a result, discontinuation is recommended for many long-term users. The <a href="/wiki/Withdrawal_syndrome_from_benzodiazepines" title="Withdrawal syndrome from benzodiazepines" class="mw-redirect">withdrawal syndrome from benzodiazepines</a> can range from a mild and short-lasting syndrome to a prolonged and severe syndrome. Withdrawal symptoms can lead to continued use of benzodiazepines for many years, long after the original reason for taking benzodiazepines has passed. Many patients know that the benzodiazepines no longer work for them but are unable to discontinue benzodiazepines because of withdrawal symptoms.<sup id="cite_ref-ashman_38-3" class="reference"><a href="#cite_note-ashman-38"><span>[</span>38<span>]</span></a></sup></p>
<p>Withdrawal symptoms can emerge despite slow reduction but can be reduced by a slower rate of withdrawal. As a result, withdrawal rates have been recommended to be customized to each individual patient. The time needed to withdrawal can vary from a couple of months to a year or more and often depends on length of use, dosage taken, lifestyle, health, and social and environmental stress factors.<sup id="cite_ref-ashman_38-4" class="reference"><a href="#cite_note-ashman-38"><span>[</span>38<span>]</span></a></sup></p>
<p><a href="/wiki/Diazepam" title="Diazepam">Diazepam</a> is often recommended due to its long elimination half-life and also because of its availability in low potency doses. The non-benzodiazepine Z drugs such as zolpidem, zaleplon, and zopiclone should not be used as a replacement for benzodiazepines, as they have a similar mechanism of action and can induce a similar dependence. The pharmacological mechanism of benzodiazepine tolerance and dependence is the internalization (removal) of receptor site in the brain and changes in gene transcription codes in the brain.<sup id="cite_ref-ashman_38-5" class="reference"><a href="#cite_note-ashman-38"><span>[</span>38<span>]</span></a></sup></p>
<p>With long-term use and during withdrawal of benzodiazepines, treatment-emergent depression and<sup id="cite_ref-asapdacg_6-2" class="reference"><a href="#cite_note-asapdacg-6"><span>[</span>6<span>]</span></a></sup> <a href="/wiki/Apathy" title="Apathy">emotional blunting</a> may emerge and sometimes also suicidal ideation. There is evidence that the higher the dose used the more likely it is benzodiazepine use will induce these feelings. Reducing the dose or discontinuing benzodiazepines may be indicated in such cases. Withdrawal symptoms can persist for quite some time after discontinuing benzodiazepines. Some common protracted withdrawal symptoms include <a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, <a href="/wiki/Clinical_depression" title="Clinical depression" class="mw-redirect">depression</a>, <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, and physical symptoms such as <a href="/wiki/Gastrointestinal" title="Gastrointestinal" class="mw-redirect">gastrointestinal</a>, neurologic, and <a href="/wiki/Musculoskeletal" title="Musculoskeletal" class="mw-redirect">musculoskeletal</a> effects. The protracted withdrawal state may still occur despite slow titration of dosage. It is believed that the protracted withdrawal effects are due to persisting neuroadaptations.<sup id="cite_ref-pmid10779253_10-2" class="reference"><a href="#cite_note-pmid10779253-10"><span>[</span>10<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prevention">Prevention</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=10" title="Edit section: Prevention">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Due to the risk of developing tolerance, dependence, and adverse health effects,<sup id="cite_ref-sbtp2_44-0" class="reference"><a href="#cite_note-sbtp2-44"><span>[</span>44<span>]</span></a></sup> such as cognitive impairment,<sup id="cite_ref-Heberlein_A_7.E2.80.9315_18-1" class="reference"><a href="#cite_note-Heberlein_A_7.E2.80.9315-18"><span>[</span>18<span>]</span></a></sup> benzodiazepines are indicated for short-term use only - a few weeks, followed by a gradual dose reduction.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45"><span>[</span>45<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="The_Committee_on_the_Review_of_Medicines_.28UK.29">The Committee on the Review of Medicines (UK)</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=11" title="Edit section: The Committee on the Review of Medicines (UK)">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The Committee on the Review of Medicines carried out a review into benzodiazepines due to significant concerns of tolerance, <a href="/wiki/Drug_dependence" title="Drug dependence" class="mw-redirect">drug dependence</a>, benzodiazepine withdrawal problems, and other adverse effects and published the results in the British Medical Journal in March 1980. The committee found that benzodiazepines do not have any <a href="/wiki/Antidepressant" title="Antidepressant">antidepressant</a> or <a href="/wiki/Analgesic" title="Analgesic">analgesic</a> properties and are, therefore, unsuitable treatments for conditions such as depression, <a href="/wiki/Tension_headaches" title="Tension headaches" class="mw-redirect">tension headaches</a>, and <a href="/wiki/Dysmenorrhea" title="Dysmenorrhea">dysmenorrhea</a>. Benzodiazepines are also not beneficial in the treatment of <a href="/wiki/Psychosis" title="Psychosis">psychosis</a>. The committee also recommended against benzodiazepines for use in the treatment of <a href="/wiki/Anxiety" title="Anxiety">anxiety</a> or <a href="/wiki/Insomnia" title="Insomnia">insomnia</a> in children.<sup id="cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-0" class="reference"><a href="#cite_note-Committee_on_the_Review_of_Medicines_910.E2.80.932-46"><span>[</span>46<span>]</span></a></sup></p>
<p>The committee was in agreement with the <a href="/wiki/Institute_of_Medicine" title="Institute of Medicine">Institute of Medicine</a> (USA) and the conclusions of a study carried out by the <a href="/wiki/White_House_Office_of_Drug_Policy" title="White House Office of Drug Policy" class="mw-redirect">White House Office of Drug Policy</a> and the <a href="/wiki/National_Institute_on_Drug_Abuse" title="National Institute on Drug Abuse">National Institute on Drug Abuse</a> (USA) that there is little evidence that long-term use of benzodiazepine hypnotics are beneficial in the treatment of insomnia due to the development of tolerance. Benzodiazepines tend to lose their sleep-promoting properties within 3–14 days of continuous use, and, in the treatment of anxiety, the committee found that there was little convincing evidence that benzodiazepines retains efficacy in the treatment of anxiety after 4 months of continuous use due to the development of tolerance.<sup id="cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-1" class="reference"><a href="#cite_note-Committee_on_the_Review_of_Medicines_910.E2.80.932-46"><span>[</span>46<span>]</span></a></sup></p>
<p>The committee found that the regular use of benzodiazepines causes the development of dependence characterized by tolerance to the therapeutic effects of benzodiazepines and the development of the benzodiazepine withdrawal syndrome including symptoms such as <a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, <a href="/wiki/Apprehension_(fear)" title="Apprehension (fear)" class="mw-redirect">apprehension</a>, <a href="/wiki/Tremor" title="Tremor">tremors</a>, <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, <a href="/wiki/Nausea" title="Nausea">nausea</a>, and <a href="/wiki/Vomiting" title="Vomiting">vomiting</a> upon cessation of benzodiazepine use. Withdrawal symptoms tend to develop within 24 hours upon cessation of short-acting benzodiazepines, and 3–10 days after cessation of longer-acting benzodiazepines. Withdrawal effects could occur after treatment, lasting only 2 weeks at therapeutic dose levels; however, withdrawal effects tend to occur with habitual use beyond 2 weeks and are more likely the higher the dose. The withdrawal symptoms may appear to be similar to the original condition.<sup id="cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-2" class="reference"><a href="#cite_note-Committee_on_the_Review_of_Medicines_910.E2.80.932-46"><span>[</span>46<span>]</span></a></sup></p>
<p>The committee recommended that all benzodiazepine treatment be withdrawn gradually and recommended that benzodiazepine treatment be used only in carefully selected patients and that therapy be limited to short-term use only. It was noted in the review that alcohol can potentiate the <a href="/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a>-depressant effects of benzodiazepines and should be avoided. The central nervous system-depressant effects of benzodiazepines may make driving or operating machinery dangerous, and the elderly are more prone to these adverse effects. High single doses or repeated low doses have been reported to produce <a href="/wiki/Hypotonia" title="Hypotonia">hypotonia</a>, poor sucking, and <a href="/wiki/Hypothermia" title="Hypothermia">hypothermia</a> in the <a href="/wiki/Neonate" title="Neonate" class="mw-redirect">neonate</a>, and irregularities in the <a href="/wiki/Fetal" title="Fetal" class="mw-redirect">fetal</a> heart. The committee recommended that benzodiazepines be avoided in <a href="/wiki/Lactation" title="Lactation">lactation</a>.<sup id="cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-3" class="reference"><a href="#cite_note-Committee_on_the_Review_of_Medicines_910.E2.80.932-46"><span>[</span>46<span>]</span></a></sup></p>
<p>The committee recommended that withdrawal from benzodiazepines be gradual, as abrupt withdrawal from high doses of benzodiazepines may cause <a href="/wiki/Confusion" title="Confusion" class="mw-redirect">confusion</a>, <a href="/wiki/Toxic_psychosis" title="Toxic psychosis" class="mw-redirect">toxic psychosis</a>, <a href="/wiki/Convulsions" title="Convulsions" class="mw-redirect">convulsions</a>, or a condition resembling <a href="/wiki/Delirium_tremens" title="Delirium tremens">delirium tremens</a>. Abrupt withdrawal from lower doses may cause depression, <a href="/wiki/Anxiety" title="Anxiety">nervousness</a>, <a href="/wiki/Rebound_insomnia" title="Rebound insomnia" class="mw-redirect">rebound insomnia</a>, <a href="/wiki/Irritability" title="Irritability">irritability</a>, <a href="/wiki/Sweating" title="Sweating" class="mw-redirect">sweating</a>, and <a href="/wiki/Diarrhea" title="Diarrhea">diarrhea</a>.<sup id="cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-4" class="reference"><a href="#cite_note-Committee_on_the_Review_of_Medicines_910.E2.80.932-46"><span>[</span>46<span>]</span></a></sup></p>
<p>The committee also made a mistake concluding:<sup id="cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-5" class="reference"><a href="#cite_note-Committee_on_the_Review_of_Medicines_910.E2.80.932-46"><span>[</span>46<span>]</span></a></sup></p>
<blockquote class="templatequote">
<p>on the present available evidence, the true addiction potential of benzodiazepines was low. The number dependant on the benzodiazepines in the UK from 1960 to 1977 has been estimated to be 28 persons. This is equivalent to a dependance rate of 5-10 cases per million patient months.</p>
</blockquote>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=12" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>For a diagnosis of benzodiazepine dependence to be made, the ICD-10 requires that at least 3 of the below criteria are met and that they have been present for at least a month, or, if less than a month, that they appeared repeatedly during a 12-month period.<sup id="cite_ref-evidence_based_diagnosis_in_primary_care_47-0" class="reference"><a href="#cite_note-evidence_based_diagnosis_in_primary_care-47"><span>[</span>47<span>]</span></a></sup><sup id="cite_ref-48" class="reference"><a href="#cite_note-48"><span>[</span>48<span>]</span></a></sup></p>
<ul>
<li>Behavioral, cognitive, and physiological phenomena that are associated with the repeated use and that typically include a strong desire to take the drug.</li>
<li><a href="/wiki/Benzodiazepine_misuse" title="Benzodiazepine misuse">Difficulty controlling use</a></li>
<li><a href="/wiki/Long-term_effects_of_benzodiazepines" title="Long-term effects of benzodiazepines" class="mw-redirect">Continued use despite harmful consequences</a></li>
<li>Preference given to drug use rather than to other activities and obligations</li>
<li>Increased tolerance to effects of the drug and sometimes a <a href="/wiki/Benzodiazepine_withdrawal_syndrome" title="Benzodiazepine withdrawal syndrome">physical withdrawal state</a>.</li>
</ul>
<p>These diagnostic criteria are good for research purposes, but, in everyday clinical practice, they should be interpreted according to clinical judgement. In clinical practice, benzodiazepine dependence should be suspected in those having used benzodiazepines for longer than a month, in particular, if they are from a high-risk group. The main factors associated with an increased incidence of benzodiazepine dependence include:<sup id="cite_ref-evidence_based_diagnosis_in_primary_care_47-1" class="reference"><a href="#cite_note-evidence_based_diagnosis_in_primary_care-47"><span>[</span>47<span>]</span></a></sup></p>
<ul>
<li>Dose</li>
<li>Duration</li>
<li>Concomitant use of antidepressants</li>
</ul>
<p>Benzodiazepine dependence should be suspected also in individuals having substance use disorders including alcohol, and should be suspected in individuals obtaining their own supplies of benzodiazepines. Benzodiazepine dependence is almost certain in individuals who are members of a tranquillizer self-help groups.<sup id="cite_ref-evidence_based_diagnosis_in_primary_care_47-2" class="reference"><a href="#cite_note-evidence_based_diagnosis_in_primary_care-47"><span>[</span>47<span>]</span></a></sup></p>
<p>Research has found that about 40 percent of people with a diagnosis of benzodiazepine dependence are not aware that they are dependent on benzodiazepines, whereas about 11 percent of people judged not to be dependent believe that they are. When assessing a person for benzodiazepine dependence, asking specific questions rather than questions based on concepts is recommended by experts as the best approach of getting a more accurate diagnosis. For example, asking persons if they "think about the medication at times of the day other than when they take the drug" would provide a more meaningful answer than asking "do you think you are psychologically dependent?".<sup id="cite_ref-evidence_based_diagnosis_in_primary_care_47-3" class="reference"><a href="#cite_note-evidence_based_diagnosis_in_primary_care-47"><span>[</span>47<span>]</span></a></sup> The <a rel="nofollow" class="external text" href="http://cckan.ruhosting.nl/benengli.htm">Benzodiazepine Dependence Self Report Questionnaire</a> is one questionnaire used to assess and diagnose benzodiazepine dependence.<sup id="cite_ref-evidence_based_diagnosis_in_primary_care_47-4" class="reference"><a href="#cite_note-evidence_based_diagnosis_in_primary_care-47"><span>[</span>47<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="In_the_elderly">In the elderly</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=13" title="Edit section: In the elderly">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="hatnote">See also: <a href="/wiki/Benzodiazepine_withdrawal_syndrome#Elderly" title="Benzodiazepine withdrawal syndrome">Benzodiazepine withdrawal syndrome § Elderly</a></div>
<p>Long-term use and benzodiazepine dependence is a serious problem in the elderly. Failure to treat benzodiazepine dependence in the elderly can cause serious medical complications.<sup id="cite_ref-49" class="reference"><a href="#cite_note-49"><span>[</span>49<span>]</span></a></sup> The elderly have less <a href="/wiki/Cognitive_reserve" title="Cognitive reserve">cognitive reserve</a> and are more sensitive to the short (e.g., in between dose withdrawal) and protracted withdrawal effects of benzodiazepines, as well as the side-effects both from short-term and long-term use. This can lead to excessive contact with their doctor. Research has found that withdrawing elderly people from benzodiazepines leads to a significant reduction in doctor visits per year, it is presumed, due to an elimination of drug side-effects and withdrawal effects.<sup id="cite_ref-pmid10779253_10-3" class="reference"><a href="#cite_note-pmid10779253-10"><span>[</span>10<span>]</span></a></sup></p>
<p><a href="/wiki/Tobacco" title="Tobacco">Tobacco</a> and <a href="/wiki/Ethanol" title="Ethanol">alcohol</a> are the most common substances that <a href="/wiki/Elderly" title="Elderly" class="mw-redirect">elderly</a> people get a <a href="/wiki/Substance_dependence" title="Substance dependence">dependence</a> on or <a href="/wiki/Drug_misuse" title="Drug misuse" class="mw-redirect">misuse</a>. The next-most-common substance that elderly people develop a <a href="/wiki/Drug_dependence" title="Drug dependence" class="mw-redirect">drug dependence</a> to and/or misuse is <a href="/wiki/Benzodiazepines" title="Benzodiazepines" class="mw-redirect">benzodiazepines</a>. Drug-induced cognitive problems can have serious consequences for elderly people and can lead to confusional states and "pseudo-dementia". About 10% of elderly patients referred to <a href="/wiki/Memory_clinic" title="Memory clinic">memory clinics</a> actually have a drug-induced cause that most often is benzodiazepines. Benzodiazepines have also been linked to an increased risk of <a href="/wiki/Road_traffic_accidents" title="Road traffic accidents" class="mw-redirect">road traffic accidents</a> and <a href="/wiki/Falling_(accident)" title="Falling (accident)">falls</a> in the elderly. The long-term effects of benzodiazepines are still not fully understood in the elderly or any age group. Long-term benzodiazepine use is associated with attentional and visuospatial functional impairments. Withdrawal from benzodiazepines can lead to improved <a href="/wiki/Alertness" title="Alertness">alertness</a> and decreased <a href="/wiki/Forgetfulness" title="Forgetfulness" class="mw-redirect">forgetfulness</a> in the elderly. Withdrawal led to statistical significant improvements in memory function and performance related skills in those having withdrawn successfully from benzodiazepines, whereas those having remained on benzodiazepines experienced worsening symptoms. People having withdrawn from benzodiazepines also felt their sleep was more refreshing, making statements such as "<i>I feel sharper when I wake up</i>" or "<i>I feel better, more awake</i>", or "<i>It used to take me an hour to fully wake up.</i>" This suggests that benzodiazepines may actually make insomnia worse in the elderly.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50"><span>[</span>50<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Treatment_and_prevention">Treatment and prevention</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=14" title="Edit section: Treatment and prevention">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Benzodiazepines are regarded as a highly addictive drug class.<sup id="cite_ref-pmid22572594_51-0" class="reference"><a href="#cite_note-pmid22572594-51"><span>[</span>51<span>]</span></a></sup> A psychological and <a href="/wiki/Physical_dependence" title="Physical dependence">physical dependence</a> can develop in as short as a few weeks but may take years to develop in other individuals. Patients wanting to withdraw from benzodiazepines typically receive little advice or support, and such withdrawal should be by small increments over a period of months.<sup id="cite_ref-afr.2009_52-0" class="reference"><a href="#cite_note-afr.2009-52"><span>[</span>52<span>]</span></a></sup></p>
<p>Benzodiazepines are usually prescribed only short-term, as there is little justification for their prescribing long-term.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53"><span>[</span>53<span>]</span></a></sup> Some doctors however, disagree and believe long-term use beyond 4 weeks is sometimes justified, although there is little data to support this viewpoint.<sup id="cite_ref-sbtp_9-1" class="reference"><a href="#cite_note-sbtp-9"><span>[</span>9<span>]</span></a></sup> Such viewpoints are a minority in the medical literature.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54"><span>[</span>54<span>]</span></a></sup></p>
<p>There is no evidence that "drug holidays" or periods of abstinence reduced the risk of dependence; there is evidence from animal studies that such an approach does not prevent dependence from happening. Use of short-acting benzodiazepines is associated with interdose withdrawal symptoms, which may increase the risk of <a href="/wiki/Kindling_(substance_withdrawal)" title="Kindling (substance withdrawal)" class="mw-redirect">kindling</a>; kindling has clinical relevance with regard to benzodiazepines; for example, there is an increasing shift to use of benzodiazepines with a shorter half-life and intermitant use, which can result in interdose withdrawal and rebound effects.<sup id="cite_ref-Allison-2003_5-5" class="reference"><a href="#cite_note-Allison-2003-5"><span>[</span>5<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Flumazenil_as_treatment_for_benzodiazepine_dependence">Flumazenil as treatment for benzodiazepine dependence</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=15" title="Edit section: Flumazenil as treatment for benzodiazepine dependence">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In Italy, the gold standard for treatment of high-dose benzodiazepine dependency is 8–10 days of low dose, slow infusion of <a href="/wiki/Flumazenil" title="Flumazenil">flumazenil</a>.<sup id="cite_ref-LugoboniFaccini2011_55-0" class="reference"><a href="#cite_note-LugoboniFaccini2011-55"><span>[</span>55<span>]</span></a></sup> One addiction treatment centre in Italy has used flumazenil to treat over 300 patients who are dependent on high doses of benzodiazepines (up to 70 times higher than conventionally prescribed) with doctors being one of their most common patients.<sup id="cite_ref-LugoboniLeone2012_56-0" class="reference"><a href="#cite_note-LugoboniLeone2012-56"><span>[</span>56<span>]</span></a></sup></p>
<p>Epileptic patients who have become tolerant to the anti-seizure effects of the benzodiazepine clonazepam became seizure-free for several days after treatment with 1.5&#160;mg flumazenil.<sup id="cite_ref-Savic1991_57-0" class="reference"><a href="#cite_note-Savic1991-57"><span>[</span>57<span>]</span></a></sup> Similarly, patients who were dependent on high doses of benzodiazepines (median dosage equal to 333&#160;mg diazepam-equivalent) were able to be stabilised on a low dose of clonazepam after 7–8 days of treatment with flumazenil.<sup id="cite_ref-QuaglioPattaro2012_58-0" class="reference"><a href="#cite_note-QuaglioPattaro2012-58"><span>[</span>58<span>]</span></a></sup></p>
<p>Flumazenil has been compared to placebo in dependent subjects, whereby typical benzodiazepine effects were reversed with little to no withdrawal symptoms.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59"><span>[</span>59<span>]</span></a></sup> Flumazenil was shown to produce significantly less withdrawal symptoms than saline in a randomized, placebo-controlled study with benzodiazepine dependent subjects. Additionally, relapse rates were much less during subsequent follow-up.<sup id="cite_ref-GerraZaimovic2002_60-0" class="reference"><a href="#cite_note-GerraZaimovic2002-60"><span>[</span>60<span>]</span></a></sup></p>
<p>Several studies have shown enhancement of the benzodiazepine binding site after chronic treatment with flumazenil where sites have become more numerous and uncoupling/down-regulation of GABAA has been reversed.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61"><span>[</span>61<span>]</span></a></sup><sup id="cite_ref-62" class="reference"><a href="#cite_note-62"><span>[</span>62<span>]</span></a></sup><sup id="cite_ref-63" class="reference"><a href="#cite_note-63"><span>[</span>63<span>]</span></a></sup> After long-term exposure to benzodiazepines, GABAA receptors become down-regulated and uncoupled. Growth of new receptors and recoupling after prolonged flumazenil exposure has also been observed. It is thought this may be due to increased synthesis of receptor proteins.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64"><span>[</span>64<span>]</span></a></sup></p>
<p>Flumazenil was found to be more effective than placebo in reducing feelings of hostility and aggression in patients who had been free of benzodiazepines for 4–266 weeks.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65"><span>[</span>65<span>]</span></a></sup> This may suggest a role for flumazenil in treating protracted benzodiazepine withdrawal symptoms.</p>
<h3><span class="mw-headline" id="Letter_to_patients">Letter to patients</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=16" title="Edit section: Letter to patients">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Sending a letter to patients warning of the adverse effects of long-term use of benzodiazepines and recommending dosage reduction has been found to be successful and a cost-effective strategy in reducing benzodiazepine consumption in general practice. Within a year of the letter's going out, there was found to be a 17% fall in the number of benzodiazepines being prescribed, with 5% of patients having totally discontinued benzodiazepines.<sup id="cite_ref-66" class="reference"><a href="#cite_note-66"><span>[</span>66<span>]</span></a></sup><sup id="cite_ref-67" class="reference"><a href="#cite_note-67"><span>[</span>67<span>]</span></a></sup> A study in Holland reported a higher success rate by sending a letter to patients who are benzodiazepine-dependent. The results of the Dutch study reported 11.3% of patients discontinuing benzodiazepines completely within a year.<sup id="cite_ref-68" class="reference"><a href="#cite_note-68"><span>[</span>68<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Pharmacist_intervention_programs">Pharmacist intervention programs</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=17" title="Edit section: Pharmacist intervention programs">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A study found that pharmacists providing educational sessions for medical staff at nursing homes for the elderly combined with medicine audits and feedback cycles combined with an interdisciplinary sedative review resulted in a large reduction in both the number of residents taking <a href="/wiki/Benzodiazepines" title="Benzodiazepines" class="mw-redirect">benzodiazepines</a> or <a href="/wiki/Antipsychotics" title="Antipsychotics" class="mw-redirect">antipsychotics</a> at all as well as an overall reduction in total dosage.<sup id="cite_ref-69" class="reference"><a href="#cite_note-69"><span>[</span>69<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Cognitive_behavioral_therapy">Cognitive behavioral therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=18" title="Edit section: Cognitive behavioral therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Zopiclone" title="Zopiclone">Zopiclone</a> is the most frequently prescribed hypnotic in the UK, followed by <a href="/wiki/Nitrazepam" title="Nitrazepam">nitrazepam</a>, and then <a href="/wiki/Temazepam" title="Temazepam">temazepam</a>, which is the most strictly regulated benzodiazepine in the UK due to its popularity as a drug of abuse and due to its considerably more toxic nature. Hypnotic drugs are of poor value for the management of chronic insomnia. Hypnotic drug consumption has been shown to reduce work performance, increase absenteeism, increase road traffic accidents, increase morbidity, and increase mortality, and is associated with an increased incidence of deliberate <a href="/wiki/Self-harm" title="Self-harm">self-harm</a>. In the elderly, increases in falls and fractures associated with sedative hypnotic drug use has been found. It is widely accepted that hypnotic drug usage beyond 4 weeks is undesirable for all age groups of patients. Many continuous hypnotic users exhibit disturbed sleep as a consequence of tolerance but experience worsening rebound or withdrawal insomnia when the dose is reduced too quickly, which compounds the problem of chronic hypnotic drug use. <a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">Cognitive behavioral therapy</a> has been found to be more effective for the long-term management of insomnia than sedative hypnotic drugs. No formal withdrawal programs for benzodiazepines exists with local providers in the UK. Meta-analysis of published data on psychological treatments for insomnia show a success rate between 70 and 80%. A largescale trial utilizing <a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">cognitive behavioral therapy</a> in chronic users of sedative hypnotics including nitrazepam, temazepam, and zopiclone found <a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">CBT</a> to be a significantly more effective long-term treatment for chronic insomnia than sedative hypnotic drugs. Persisting improvements in sleep quality, sleep onset latency, increased total sleep, improvements in sleep efficiency, significant improvements in vitality, physical and mental health at 3-, 6-, and 12-month follow-ups were found in those receiving CBT. A marked reduction in total sedative hypnotic drug use was found in those receiving CBT, with 33% reporting zero hypnotic drug use. Age has been found not to be a barrier to successful outcome of CBT. It was concluded that CBT for the management of chronic insomnia is a flexible, practical, and cost-effective treatment, and it was also concluded that CBT leads to a reduction of benzodiazepine drug intake in a significant number of patients.<sup id="cite_ref-70" class="reference"><a href="#cite_note-70"><span>[</span>70<span>]</span></a></sup> Chronic use of hypnotic medications is not recommended due to their adverse effects on health and the risk of <a href="/wiki/Drug_dependence" title="Drug dependence" class="mw-redirect">dependence</a>. A gradual taper is usual clinical course in getting people off of benzodiazepines, but, even with gradual reduction, a large proportion of people fail to stop taking benzodiazepines. The elderly are particularly sensitive to the adverse effects of <a href="/wiki/Hypnotic" title="Hypnotic">hypnotic</a> medications. A clinical trial in elderly people dependent on <a href="/wiki/Benzodiazepine" title="Benzodiazepine">benzodiazepine</a> hypnotics showed that the addition of CBT to a gradual benzodiazepine reduction program increased the success rate of discontinuing benzodiazepine <a href="/wiki/Hypnotic" title="Hypnotic">hypnotic</a> drugs from 38% to 77% and at the 12-month follow-up from 24% to 70%. The paper concluded that CBT is an effective tool for reducing <a href="/wiki/Hypnotic" title="Hypnotic">hypnotic</a> use in the elderly and reducing the adverse health effects that are associated with hypnotics such as <a href="/wiki/Drug_dependence" title="Drug dependence" class="mw-redirect">drug dependence</a>, cognitive impairments, and increased road traffic accidents.<sup id="cite_ref-71" class="reference"><a href="#cite_note-71"><span>[</span>71<span>]</span></a></sup></p>
<p>A study of patients undergoing benzodiazepine withdrawal who had a diagnosis of <a href="/wiki/Generalized_anxiety_disorder" title="Generalized anxiety disorder">generalized anxiety disorder</a> showed that those having received CBT had a very high success rate of discontinuing benzodiazepines compared to those not having receive CBT. This success rate was maintained at the 12-month follow-up. Furthermore it was found that, in patients having discontinued <a href="/wiki/Benzodiazepines" title="Benzodiazepines" class="mw-redirect">benzodiazepines</a>, they no longer met the diagnosis of <a href="/wiki/General_anxiety_disorder" title="General anxiety disorder" class="mw-redirect">general anxiety disorder</a>, and that the number of patients no longer meeting the diagnosis of general anxiety disorder was higher in the group having received CBT. Thus, CBT can be an effective tool to add to a gradual benzodiazepine dosage reduction program leading to improved and sustained <a href="/wiki/Mental_health" title="Mental health">mental health</a> benefits.<sup id="cite_ref-72" class="reference"><a href="#cite_note-72"><span>[</span>72<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Legal_implications">Legal implications</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=19" title="Edit section: Legal implications">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Negligent management of the benzodiazepine withdrawal syndrome has led to some doctors' being brought before the <a href="/wiki/General_Medical_Council" title="General Medical Council">General Medical Council</a> in the UK, for example, for stopping sleeping tablets abruptly or reducing anxiolytics too quickly, failure to initiate replacement therapy (e.g., equivalent dose of diazepam), failure to increase dosage to alleviate severe withdrawal effects, and failure to warn the patient of the possibility of withdrawal symptoms, having led to a finding by the GMC of negligence against one doctor.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73"><span>[</span>73<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=20" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Research studies have come to different conclusions on the number of therapeutic dose users who develop a physical dependence and withdrawal syndrome. Estimates by researchers of the number of people affected range 20–100% of patients prescribed benzodiazepines at therapeutic dosages long term are physically dependent and will experience withdrawal symptoms.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74"><span>[</span>74<span>]</span></a></sup></p>
<p>Benzodiazepines can be addictive and induce dependence even at low doses, with 23% becoming addicted within 3 months of use. Benzodiazepine addiction is considered a public health problem. Approximately 68.5% of prescriptions of benzodiazepines originate from local health centers, with psychiatry and general hospitals accounting for 10% each. A survey of general practitioners reported that the reason for initiating benzodiazepines was due to an empathy for the patients suffering and a lack of other therapeutic options rather than patients demanding them. However, long-term use was more commonly at the insistence of the patient, it is presumed, because <a href="/wiki/Physical_dependence" title="Physical dependence">physical dependence</a> and/or addiction had developed.<sup id="cite_ref-pmid18041658_75-0" class="reference"><a href="#cite_note-pmid18041658-75"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-76" class="reference"><a href="#cite_note-76"><span>[</span>76<span>]</span></a></sup><sup id="cite_ref-77" class="reference"><a href="#cite_note-77"><span>[</span>77<span>]</span></a></sup></p>
<p>Approximately twice as many women as men are prescribed benzodiazepines. It is believed that this is largely because men typically turned to alcohol to cope with stress and women to prescription drugs. Biased perception of women by male doctors may also play a role in increased prescribing rates to women; however, increased anxiety features in women does not account for the wide gap alone between men and women.<sup id="cite_ref-bdmrch2005_20-1" class="reference"><a href="#cite_note-bdmrch2005-20"><span>[</span>20<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=21" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Previously, physical dependence on benzodiazepines was largely thought to occur only in people on high-therapeutic-dose ranges and low- or normal-dose dependence was not suspected until the 1970s; and it was not until the early 1980s that it was confirmed.<sup id="cite_ref-78" class="reference"><a href="#cite_note-78"><span>[</span>78<span>]</span></a></sup><sup id="cite_ref-79" class="reference"><a href="#cite_note-79"><span>[</span>79<span>]</span></a></sup> Low-dose dependence has now been clearly demonstrated in both animal studies and human studies,<sup id="cite_ref-80" class="reference"><a href="#cite_note-80"><span>[</span>80<span>]</span></a></sup><sup id="cite_ref-81" class="reference"><a href="#cite_note-81"><span>[</span>81<span>]</span></a></sup> and is a recognized <a href="/wiki/Illness" title="Illness" class="mw-redirect">clinical</a> disadvantage of benzodiazepines. Severe withdrawal syndromes can occur from these low doses of benzodiazepines even after gradual dose reduction.<sup id="cite_ref-82" class="reference"><a href="#cite_note-82"><span>[</span>82<span>]</span></a></sup><sup id="cite_ref-83" class="reference"><a href="#cite_note-83"><span>[</span>83<span>]</span></a></sup> An estimated 30–45% of chronic low-dose benzodiazepine users are dependent and it has been recommended that benzodiazepines even at low dosage be prescribed for a maximum of 7–14 days to avoid dependence.<sup id="cite_ref-84" class="reference"><a href="#cite_note-84"><span>[</span>84<span>]</span></a></sup> As a result strict regulations for the prescription of benzodiazepines due to this risk of low-dose dependence.<sup id="cite_ref-pmid22413490_85-0" class="reference"><a href="#cite_note-pmid22413490-85"><span>[</span>85<span>]</span></a></sup></p>
<p>Some <a href="/wiki/Controversy" title="Controversy">controversy</a> remains, however, in the medical literature as to the exact nature of low-dose dependence and the difficulty in getting patients to discontinue their benzodiazepines, with some papers attributing the problem to predominantly drug-seeking behavior and drug craving, whereas other papers having found the opposite, attributing the problem to a problem of physical dependence with drug-seeking and craving not being typical of low-dose benzodiazepine users.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86"><span>[</span>86<span>]</span></a></sup><sup id="cite_ref-87" class="reference"><a href="#cite_note-87"><span>[</span>87<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Misuse_and_addiction">Misuse and addiction</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=22" title="Edit section: Misuse and addiction">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Ativan05mg.jpg" class="image"><img alt="A picture of Ativan brand lorazepam tablets" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/96/Ativan05mg.jpg/220px-Ativan05mg.jpg" width="220" height="240" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/96/Ativan05mg.jpg/330px-Ativan05mg.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/96/Ativan05mg.jpg/440px-Ativan05mg.jpg 2x" data-file-width="1200" data-file-height="1309" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Ativan05mg.jpg" class="internal" title="Enlarge"></a></div>
<a href="/wiki/Lorazepam" title="Lorazepam">Lorazepam</a> (Ativan) tablets.</div>
</div>
</div>
<div class="hatnote">See also: <a href="/wiki/Benzodiazepine_misuse" title="Benzodiazepine misuse">Benzodiazepine misuse</a></div>
<p>Benzodiazepines are one of the largest classes of abused drugs; they are classed as schedule IV controlled drugs because of their recognized medical uses.<sup id="cite_ref-88" class="reference"><a href="#cite_note-88"><span>[</span>88<span>]</span></a></sup> Across the world the most frequently diverted and abused benzodiazepines include temazepam, diazepam, nimetazepam, nitrazepam, triazolam, flunitrazepam, midazolam, and in the United States alprazolam, clonazepam, and lorazepam.</p>
<p>Benzodiazepines can cause serious addiction problems. A survey in <a href="/wiki/Senegal" title="Senegal">Senegal</a> of doctors found that many doctors feel that their training and knowledge of benzodiazepines is, in general, poor; a study in <a href="/wiki/Dakar" title="Dakar">Dakar</a> found that almost one-fifth of doctors ignored prescribing guidelines regarding short-term use of benzodiazepines, and almost three-quarters of doctors regarded their training and knowledge of benzodiazepines to be inadequate. More training regarding benzodiazepines has been recommended for doctors.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89"><span>[</span>89<span>]</span></a></sup> Due to the serious concerns of addiction, national governments were recommended to urgently seek to raise knowledge via training about the addictive nature of benzodiazepines and appropriate prescribing of benzodiazepines.<sup id="cite_ref-90" class="reference"><a href="#cite_note-90"><span>[</span>90<span>]</span></a></sup></p>
<p>A six-year study on 51 <a href="/wiki/Vietnam_veteran" title="Vietnam veteran">Vietnam veterans</a> who were drug abusers of either mainly <a href="/wiki/Stimulants" title="Stimulants" class="mw-redirect">stimulants</a> (11 people), mainly opiates (26 people), or mainly benzodiazepines (14 people) was carried out to assess psychiatric symptoms related to the specific drugs of abuse. After six years, <a href="/wiki/Opiate" title="Opiate">opiate</a> abusers had little change in psychiatric symptomatology; five of the stimulant users had developed <a href="/wiki/Psychosis" title="Psychosis">psychosis</a>, and eight of the benzodiazepine users had developed depression. Therefore, long-term <a href="/wiki/Benzodiazepine_abuse" title="Benzodiazepine abuse" class="mw-redirect">benzodiazepine abuse</a> and dependence seems to carry a negative effect on <a href="/wiki/Mental_health" title="Mental health">mental health</a>, with a significant risk of causing depression.<sup id="cite_ref-91" class="reference"><a href="#cite_note-91"><span>[</span>91<span>]</span></a></sup> Benzodiazepines are also sometimes abused intra-nasally.<sup id="cite_ref-92" class="reference"><a href="#cite_note-92"><span>[</span>92<span>]</span></a></sup></p>
<p>In the <a href="/wiki/Elderly" title="Elderly" class="mw-redirect">elderly</a>, <a href="/wiki/Ethanol" title="Ethanol">alcohol</a> and benzodiazepines are the most commonly abused substances, and the elderly population is more susceptible to <a href="/wiki/Benzodiazepine_withdrawal_syndrome" title="Benzodiazepine withdrawal syndrome">benzodiazepine withdrawal syndrome</a> and <a href="/wiki/Delirium" title="Delirium">delirium</a> than are younger patients.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93"><span>[</span>93<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=23" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/Long-term_effects_of_benzodiazepines" title="Long-term effects of benzodiazepines" class="mw-redirect">Long-term effects of benzodiazepines</a></li>
<li><a href="/wiki/Alcohol_withdrawal_syndrome" title="Alcohol withdrawal syndrome">Alcohol withdrawal syndrome</a></li>
<li><a href="/wiki/Long-term_effects_of_alcohol" title="Long-term effects of alcohol" class="mw-redirect">Long-term effects of alcohol</a></li>
<li><a href="/wiki/SSRI_discontinuation_syndrome" title="SSRI discontinuation syndrome" class="mw-redirect">SSRI discontinuation syndrome</a></li>
<li><a href="/wiki/Drug_related_crime" title="Drug related crime" class="mw-redirect">Drug related crime</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=24" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-count references-column-count-2" style="-moz-column-count: 2; -webkit-column-count: 2; column-count: 2; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-pmid1679388-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid1679388_1-0">^</a></b></span> <span class="reference-text"><span class="citation journal">de Wit H; Griffiths RR (June 1991). <a rel="nofollow" class="external text" href="http://www.sciencedirect.com/science/article/pii/0376871691900543">"Testing the abuse liability of anxiolytic and hypnotic drugs in humans"</a>. <i>Drug and Alcohol Dependence</i> <b>28</b> (1): 83–111. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0376-8716%2891%2990054-3">10.1016/0376-8716(91)90054-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1679388">1679388</a><span class="reference-accessdate">. Retrieved <span class="nowrap">21 December</span> 2012</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Testing+the+abuse+liability+of+anxiolytic+and+hypnotic+drugs+in+humans&amp;rft.au=de+Wit+H&amp;rft.au=Griffiths+RR&amp;rft.aulast=de+Wit+H&amp;rft.date=June+1991&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2F0376871691900543&amp;rft_id=info%3Adoi%2F10.1016%2F0376-8716%2891%2990054-3&amp;rft_id=info%3Apmid%2F1679388&amp;rft.issue=1&amp;rft.jtitle=Drug+and+Alcohol+Dependence&amp;rft.pages=83-111&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=28" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nutt-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nutt_2-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Nutt DJ (1 January 1986). <a rel="nofollow" class="external text" href="http://www.cell.com/trends/pharmacological-sciences/abstract/0165-6147(86)90420-7">"Benzodiazepine dependence in the clinic: reason for anxiety"</a>. <i>Trends neurosci</i> <b>7</b>: 457–460. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0165-6147%2886%2990420-7">10.1016/0165-6147(86)90420-7</a><span class="reference-accessdate">. Retrieved <span class="nowrap">21 December</span> 2012</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+dependence+in+the+clinic%3A+reason+for+anxiety&amp;rft.aulast=Nutt+DJ&amp;rft.au=Nutt+DJ&amp;rft.date=1+January+1986&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cell.com%2Ftrends%2Fpharmacological-sciences%2Fabstract%2F0165-6147%2886%2990420-7&amp;rft_id=info%3Adoi%2F10.1016%2F0165-6147%2886%2990420-7&amp;rft.jtitle=Trends+neurosci&amp;rft.pages=457-460&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Uzun-2010-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-Uzun-2010_3-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Uzun S; Kozumplik O; Jakovljević M; Sedić B (Mar 2010). "Side effects of treatment with benzodiazepines". <i>Psychiatr Danub</i> <b>22</b> (1): 90–3. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20305598">20305598</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Side+effects+of+treatment+with+benzodiazepines&amp;rft.au=Jakovljevi%C4%87+M&amp;rft.au=Kozumplik+O&amp;rft.aulast=Uzun+S&amp;rft.au=Sedi%C4%87+B&amp;rft.au=Uzun+S&amp;rft.date=Mar+2010&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F20305598&amp;rft.issue=1&amp;rft.jtitle=Psychiatr+Danub&amp;rft.pages=90-3&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><span class="citation journal">O'brien CP (2005). "Benzodiazepine use, abuse, and dependence". <i>J Clin Psychiatry</i> <b>66</b> (Suppl 2): 28–33. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15762817">15762817</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+use%2C+abuse%2C+and+dependence&amp;rft.aulast=O%27brien+CP&amp;rft.au=O%27brien+CP&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F15762817&amp;rft.issue=Suppl+2&amp;rft.jtitle=J+Clin+Psychiatry&amp;rft.pages=28-33&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=66" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Allison-2003-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-Allison-2003_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Allison-2003_5-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Allison-2003_5-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Allison-2003_5-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Allison-2003_5-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Allison-2003_5-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Allison C; Pratt JA (May 2003). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S0163725803000299">"Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence"</a>. <i>Pharmacol. Ther.</i> <b>98</b> (2): 171–95. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0163-7258%2803%2900029-9">10.1016/S0163-7258(03)00029-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12725868">12725868</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Neuroadaptive+processes+in+GABAergic+and+glutamatergic+systems+in+benzodiazepine+dependence&amp;rft.au=Allison+C&amp;rft.aulast=Allison+C&amp;rft.au=Pratt+JA&amp;rft.date=May+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0163725803000299&amp;rft_id=info%3Adoi%2F10.1016%2FS0163-7258%2803%2900029-9&amp;rft_id=info%3Apmid%2F12725868&amp;rft.issue=2&amp;rft.jtitle=Pharmacol.+Ther.&amp;rft.pages=171-95&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=98" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-asapdacg-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-asapdacg_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-asapdacg_6-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-asapdacg_6-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Haddad P; Deakin B; Dursun S (27 May 2004). <a rel="nofollow" class="external text" href="http://books.google.co.uk/books?id=uV1rE_hOvJ8C&amp;pg=PA240">"Benzodiazepine dependence"</a>. <a rel="nofollow" class="external text" href="http://books.google.com/?id=uV1rE_hOvJ8C"><i>Adverse Syndromes and Psychiatric Drugs: A clinical guide</i></a>. Oxford University Press. pp.&#160;240–252. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-19-852748-0" title="Special:BookSources/978-0-19-852748-0">978-0-19-852748-0</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+dependence&amp;rft.au=Deakin+B&amp;rft.au=Dursun+S&amp;rft.au=Haddad+P&amp;rft.aulast=Haddad+P&amp;rft.btitle=Adverse+Syndromes+and+Psychiatric+Drugs%3A+A+clinical+guide&amp;rft.date=27+May+2004&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3DuV1rE_hOvJ8C&amp;rft.isbn=978-0-19-852748-0&amp;rft.pages=240-252&amp;rft.pub=Oxford+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-current_use_2009-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-current_use_2009_7-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Cloos JM; Ferreira V (January 2009). "Current use of benzodiazepines in anxiety disorders". <i>Current Opinion in Psychiatry</i> <b>22</b> (1): 90–95. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2FYCO.0b013e32831a473d">10.1097/YCO.0b013e32831a473d</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19122540">19122540</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Current+use+of+benzodiazepines+in+anxiety+disorders&amp;rft.au=Cloos+JM&amp;rft.au=Ferreira+V&amp;rft.aulast=Cloos+JM&amp;rft.date=January+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2FYCO.0b013e32831a473d&amp;rft_id=info%3Apmid%2F19122540&amp;rft.issue=1&amp;rft.jtitle=Current+Opinion+in+Psychiatry&amp;rft.pages=90-95&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18295321-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18295321_8-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Licata SC; Rowlett JK (2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2453238">"Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond."</a>. <i>Pharmacology Biochemistry and Behavior</i> <b>90</b> (1): 74–89. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pbb.2008.01.001">10.1016/j.pbb.2008.01.001</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2453238">2453238</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18295321">18295321</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Abuse+and+dependence+liability+of+benzodiazepine-type+drugs%3A+GABA%28A%29+receptor+modulation+and+beyond.&amp;rft.aulast=Licata+SC&amp;rft.au=Licata+SC&amp;rft.au=Rowlett+JK&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2453238&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pbb.2008.01.001&amp;rft_id=info%3Apmc%2F2453238&amp;rft_id=info%3Apmid%2F18295321&amp;rft.issue=1&amp;rft.jtitle=Pharmacology+Biochemistry+and+Behavior&amp;rft.pages=74-89&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=90" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-sbtp-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-sbtp_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-sbtp_9-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Puri BK; Tyrer P (28 August 1998). <a rel="nofollow" class="external text" href="http://books.google.co.uk/books?id=KTbfRIqjLtUC&amp;pg=PA149">"Clinical psychopharmacology"</a>. <a rel="nofollow" class="external text" href="http://books.google.com/?id=KTbfRIqjLtUC"><i>Sciences Basic to Psychiatry</i></a> (2nd ed.). Churchill Livingstone. pp.&#160;155–157. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-443-05514-0" title="Special:BookSources/978-0-443-05514-0">978-0-443-05514-0</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2009-07-11</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Clinical+psychopharmacology&amp;rft.aulast=Puri+BK&amp;rft.au=Puri+BK&amp;rft.au=Tyrer+P&amp;rft.btitle=Sciences+Basic+to+Psychiatry&amp;rft.date=28+August+1998&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3DKTbfRIqjLtUC&amp;rft.isbn=978-0-443-05514-0&amp;rft.pages=155-157&amp;rft.pub=Churchill+Livingstone&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10779253-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid10779253_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid10779253_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid10779253_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid10779253_10-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Longo LP; Johnson B (April 2000). <a rel="nofollow" class="external text" href="http://www.aafp.org/afp/20000401/2121.html">"Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives"</a>. <i>Am Fam Physician</i> <b>61</b> (7): 2121–8. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10779253">10779253</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Addiction%3A+Part+I.+Benzodiazepines--side+effects%2C+abuse+risk+and+alternatives&amp;rft.au=Johnson+B&amp;rft.aulast=Longo+LP&amp;rft.au=Longo+LP&amp;rft.date=April+2000&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.aafp.org%2Fafp%2F20000401%2F2121.html&amp;rft_id=info%3Apmid%2F10779253&amp;rft.issue=7&amp;rft.jtitle=Am+Fam+Physician&amp;rft.pages=2121-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Authier-2009-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-Authier-2009_11-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Authier=N; Balayssac D; Sautereau M; Zangarelli A; Courty P; Somogyi AA; Vennat B; Llorca PM; Eschalier A (Nov 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". <i>Ann Pharm Fr</i> <b>67</b> (6): 408–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pharma.2009.07.001">10.1016/j.pharma.2009.07.001</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19900604">19900604</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+dependence%3A+focus+on+withdrawal+syndrome&amp;rft.au=Authier%3DN&amp;rft.au=Balayssac+D&amp;rft.au=Courty+P&amp;rft.au=Eschalier+A&amp;rft.aulast=Authier%3DN&amp;rft.au=Llorca+PM&amp;rft.au=Sautereau+M&amp;rft.au=Somogyi+AA&amp;rft.au=Vennat+B&amp;rft.au=Zangarelli+A&amp;rft.date=Nov+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharma.2009.07.001&amp;rft_id=info%3Apmid%2F19900604&amp;rft.issue=6&amp;rft.jtitle=Ann+Pharm+Fr&amp;rft.pages=408-13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=67" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Khong-2004-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-Khong-2004_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Khong-2004_12-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Khong E; Sim MG; Hulse G (Nov 2004). <a rel="nofollow" class="external text" href="http://www.racgp.org.au/afpbackissues/2004/200410/20041031khong.pdf">"Benzodiazepine dependence"</a> <span style="font-size:85%;">(PDF)</span>. <i>Aust Fam Physician</i> <b>33</b> (11): 923–6. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15584332">15584332</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+dependence&amp;rft.au=Hulse+G&amp;rft.au=Khong+E&amp;rft.aulast=Khong+E&amp;rft.au=Sim+MG&amp;rft.date=Nov+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.racgp.org.au%2Fafpbackissues%2F2004%2F200410%2F20041031khong.pdf&amp;rft_id=info%3Apmid%2F15584332&amp;rft.issue=11&amp;rft.jtitle=Aust+Fam+Physician&amp;rft.pages=923-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=33" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><span class="citation web"><a href="/wiki/National_Treatment_Agency_for_Substance_Misuse" title="National Treatment Agency for Substance Misuse">National Treatment Agency for Substance Misuse</a> (2007). <a rel="nofollow" class="external text" href="http://www.nta.nhs.uk/publications/documents/clinical_guidelines_2007.pdf">"Drug misuse and dependence - UK guidelines on clinical management"</a> <span style="font-size:85%;">(PDF)</span>. United Kingdom: Department of Health.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.aulast=National+Treatment+Agency+for+Substance+Misuse&amp;rft.au=National+Treatment+Agency+for+Substance+Misuse&amp;rft.btitle=Drug+misuse+and+dependence+-+UK+guidelines+on+clinical+management&amp;rft.date=2007&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nta.nhs.uk%2Fpublications%2Fdocuments%2Fclinical_guidelines_2007.pdf&amp;rft.place=United+Kingdom&amp;rft.pub=Department+of+Health&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Marriott-1993-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-Marriott-1993_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Marriott-1993_14-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Marriott S; Tyrer P (August 1993). "Benzodiazepine dependence. Avoidance and withdrawal". <i>Drug safety: an international journal of medical toxicology and drug experience.</i> <b>9</b> (2): 93–103. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2165%2F00002018-199309020-00003">10.2165/00002018-199309020-00003</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8104417">8104417</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+dependence.+Avoidance+and+withdrawal&amp;rft.aulast=Marriott+S&amp;rft.au=Marriott+S&amp;rft.au=Tyrer+P&amp;rft.date=August+1993&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2165%2F00002018-199309020-00003&amp;rft_id=info%3Apmid%2F8104417&amp;rft.issue=2&amp;rft.jtitle=Drug+safety%3A+an+international+journal+of+medical+toxicology+and+drug+experience.&amp;rft.pages=93-103&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><span class="citation journal">Pétursson H (1994). "The benzodiazepine withdrawal syndrome". <i>Addiction</i> <b>89</b> (11): 1455–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1360-0443.1994.tb03743.x">10.1111/j.1360-0443.1994.tb03743.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7841856">7841856</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+benzodiazepine+withdrawal+syndrome&amp;rft.aulast=P%C3%A9tursson+H&amp;rft.au=P%C3%A9tursson+H&amp;rft.date=1994&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1360-0443.1994.tb03743.x&amp;rft_id=info%3Apmid%2F7841856&amp;rft.issue=11&amp;rft.jtitle=Addiction&amp;rft.pages=1455-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=89" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><span class="citation book">Galanter M; Kleber HD (1 July 2008). <a rel="nofollow" class="external text" href="http://books.google.com/?id=6wdJgejlQzYC"><i>The American Psychiatric Publishing Textbook of Substance Abuse Treatment</i></a> (4th ed.). United States of America: American Psychiatric Publishing Inc. p.&#160;114. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-1-58562-276-4" title="Special:BookSources/978-1-58562-276-4">978-1-58562-276-4</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.au=Galanter+M&amp;rft.au=Kleber+HD&amp;rft.aulast=Galanter+M&amp;rft.btitle=The+American+Psychiatric+Publishing+Textbook+of+Substance+Abuse+Treatment&amp;rft.date=1+July+2008&amp;rft.edition=4th&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3D6wdJgejlQzYC&amp;rft.isbn=978-1-58562-276-4&amp;rft.pages=114&amp;rft.place=United+States+of+America&amp;rft.pub=American+Psychiatric+Publishing+Inc&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><span class="citation journal">Ashton H (2005). <a rel="nofollow" class="external text" href="http://www.benzo.org.uk/amisc/ashdiag.pdf">"The diagnosis and management of benzodiazepine dependence"</a> <span style="font-size:85%;">(PDF)</span>. <i>Current Opinion in Psychiatry</i> <b>18</b> (3): 249–55. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2F01.yco.0000165594.60434.84">10.1097/01.yco.0000165594.60434.84</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16639148">16639148</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+diagnosis+and+management+of+benzodiazepine+dependence&amp;rft.au=Ashton+H&amp;rft.aulast=Ashton+H&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.benzo.org.uk%2Famisc%2Fashdiag.pdf&amp;rft_id=info%3Adoi%2F10.1097%2F01.yco.0000165594.60434.84&amp;rft_id=info%3Apmid%2F16639148&amp;rft.issue=3&amp;rft.jtitle=Current+Opinion+in+Psychiatry&amp;rft.pages=249-55&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Heberlein_A_7.E2.80.9315-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-Heberlein_A_7.E2.80.9315_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Heberlein_A_7.E2.80.9315_18-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Heberlein A; Bleich S; Kornhuber J; Hillemacher T (Jan 2009). "[Benzodiazepine dependence: causalities and treatment options]". <i>Fortschr Neurol Psychiatr</i> <b>77</b> (1): 7–15. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1055%2Fs-0028-1100831">10.1055/s-0028-1100831</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19101875">19101875</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=%5BBenzodiazepine+dependence%3A+causalities+and+treatment+options%5D&amp;rft.au=Bleich+S&amp;rft.au=Heberlein+A&amp;rft.au=Hillemacher+T&amp;rft.au=Kornhuber+J&amp;rft.aulast=Heberlein+A&amp;rft.date=Jan+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1055%2Fs-0028-1100831&amp;rft_id=info%3Apmid%2F19101875&amp;rft.issue=1&amp;rft.jtitle=Fortschr+Neurol+Psychiatr&amp;rft.pages=7-15&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=77" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><span class="citation journal">Potokar J; Coupland N; Wilson S; Rich A; Nutt D (September 1999). <a rel="nofollow" class="external text" href="http://link.springer.de/link/service/journals/00213/bibs/9146002/91460180.htm">"Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines"</a>. <i>Psychopharmacology (Berl.)</i> <b>146</b> (2): 180–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs002130051104">10.1007/s002130051104</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10525753">10525753</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Assessment+of+GABA%28A%29benzodiazepine+receptor+%28GBzR%29+sensitivity+in+patients+on+benzodiazepines&amp;rft.au=Coupland+N&amp;rft.aulast=Potokar+J&amp;rft.au=Nutt+D&amp;rft.au=Potokar+J&amp;rft.au=Rich+A&amp;rft.au=Wilson+S&amp;rft.date=September+1999&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flink.springer.de%2Flink%2Fservice%2Fjournals%2F00213%2Fbibs%2F9146002%2F91460180.htm&amp;rft_id=info%3Adoi%2F10.1007%2Fs002130051104&amp;rft_id=info%3Apmid%2F10525753&amp;rft.issue=2&amp;rft.jtitle=Psychopharmacology+%28Berl.%29&amp;rft.pages=180-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=146" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-bdmrch2005-20"><span class="mw-cite-backlink">^ <a href="#cite_ref-bdmrch2005_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-bdmrch2005_20-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Lader Prof; Morgan Prof; Shepherd Prof; Williams Dr P; Skegg Dr; Parish Prof; Tyrer Dr P; Inman Dr; Marks Dr J (Ex-Roche); Harris P (Roche); Hurry T (Wyeth) (30 October 1980 – 3 April 1981). <a rel="nofollow" class="external text" href="http://nationalarchives.gov.uk/catalogue/displaycataloguedetails.asp?CATLN=6&amp;CATID=7798554&amp;j=1">"Benzodiazepine Dependence Medical Research Council headquarters, Closed until 2014 - Opened 2005"</a> <span style="font-size:85%;">(PDF)</span>. England: <a href="/wiki/The_National_Archives_(United_Kingdom)" title="The National Archives (United Kingdom)">The National Archives</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.au=Harris+P+%28Roche%29&amp;rft.au=Hurry+T+%28Wyeth%29&amp;rft.au=Inman+Dr&amp;rft.au=Lader+Prof&amp;rft.aulast=Lader+Prof&amp;rft.au=Marks+Dr+J+%28Ex-Roche%29&amp;rft.au=Morgan+Prof&amp;rft.au=Parish+Prof&amp;rft.au=Shepherd+Prof&amp;rft.au=Skegg+Dr&amp;rft.au=Tyrer+Dr+P&amp;rft.au=Williams+Dr+P&amp;rft.btitle=Benzodiazepine+Dependence+Medical+Research+Council+headquarters%2C+Closed+until+2014+-+Opened+2005&amp;rft.date=30+October+1980+-+3+April+1981&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fnationalarchives.gov.uk%2Fcatalogue%2Fdisplaycataloguedetails.asp%3FCATLN%3D6%26CATID%3D7798554%26j%3D1&amp;rft.place=England&amp;rft.pub=The+National+Archives&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Koff_JM.2C_Pritchard_GA.2C_Greenblatt_DJ.2C_Miller_LG_1997_217.E2.80.9327-21"><span class="mw-cite-backlink">^ <a href="#cite_ref-Koff_JM.2C_Pritchard_GA.2C_Greenblatt_DJ.2C_Miller_LG_1997_217.E2.80.9327_21-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Koff_JM.2C_Pritchard_GA.2C_Greenblatt_DJ.2C_Miller_LG_1997_217.E2.80.9327_21-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Koff JM; Pritchard GA; Greenblatt DJ; Miller LG (November 1997). "The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation". <i>Pharmacology</i> <b>55</b> (5): 217–27. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1159%2F000139531">10.1159/000139531</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9399331">9399331</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+NMDA+receptor+competitive+antagonist+CPP+modulates+benzodiazepine+tolerance+and+discontinuation&amp;rft.au=Greenblatt+DJ&amp;rft.au=Koff+JM&amp;rft.aulast=Koff+JM&amp;rft.au=Miller+LG&amp;rft.au=Pritchard+GA&amp;rft.date=November+1997&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1159%2F000139531&amp;rft_id=info%3Apmid%2F9399331&amp;rft.issue=5&amp;rft.jtitle=Pharmacology&amp;rft.pages=217-27&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=55" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><span class="citation journal">Fujita M; Woods SW; Verhoeff NP et al. (March 1999). "Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans". <i>Eur. J. Pharmacol.</i> <b>368</b> (2–3): 161–72. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0014-2999%2899%2900013-8">10.1016/S0014-2999(99)00013-8</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10193652">10193652</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Changes+of+benzodiazepine+receptors+during+chronic+benzodiazepine+administration+in+humans&amp;rft.au=Fujita+M&amp;rft.aulast=Fujita+M&amp;rft.au=Verhoeff+NP&amp;rft.au=Woods+SW&amp;rft.date=March+1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0014-2999%2899%2900013-8&amp;rft_id=info%3Apmid%2F10193652&amp;rft.issue=2%E2%80%933&amp;rft.jtitle=Eur.+J.+Pharmacol.&amp;rft.pages=161-72&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=368" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><span class="citation journal">Poulos CX; Zack M (2004). "Low-dose diazepam primes motivation for <a href="/wiki/Alcohol" title="Alcohol">alcohol</a> and alcohol-related semantic networks in problem drinkers". <i>Behavioural Pharmacology</i> <b>15</b> (7): 503–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2F00008877-200411000-00006">10.1097/00008877-200411000-00006</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15472572">15472572</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Low-dose+diazepam+primes+motivation+for+alcohol+and+alcohol-related+semantic+networks+in+problem+drinkers&amp;rft.aulast=Poulos+CX&amp;rft.au=Poulos+CX&amp;rft.au=Zack+M&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2F00008877-200411000-00006&amp;rft_id=info%3Apmid%2F15472572&amp;rft.issue=7&amp;rft.jtitle=Behavioural+Pharmacology&amp;rft.pages=503-12&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><span class="citation journal">Kushner MG; Abrams K; Borchardt C (March 2000). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S0272-7358(99)00027-6">"The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings"</a>. <i>Clin Psychol Rev</i> <b>20</b> (2): 149–71. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0272-7358%2899%2900027-6">10.1016/S0272-7358(99)00027-6</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10721495">10721495</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+relationship+between+anxiety+disorders+and+alcohol+use+disorders%3A+a+review+of+major+perspectives+and+findings&amp;rft.au=Abrams+K&amp;rft.au=Borchardt+C&amp;rft.au=Kushner+MG&amp;rft.aulast=Kushner+MG&amp;rft.date=March+2000&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0272-7358%2899%2900027-6&amp;rft_id=info%3Adoi%2F10.1016%2FS0272-7358%2899%2900027-6&amp;rft_id=info%3Apmid%2F10721495&amp;rft.issue=2&amp;rft.jtitle=Clin+Psychol+Rev&amp;rft.pages=149-71&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><span class="citation journal">Khanna JM; Kalant H; Weiner J; Shah G (1992). "Rapid tolerance and cross-tolerance as predictors of chronic tolerance and cross-tolerance". <i>Pharmacol. Biochem. Behav.</i> <b>41</b> (2): 355–60. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0091-3057%2892%2990110-2">10.1016/0091-3057(92)90110-2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1574525">1574525</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Rapid+tolerance+and+cross-tolerance+as+predictors+of+chronic+tolerance+and+cross-tolerance&amp;rft.au=Kalant+H&amp;rft.au=Khanna+JM&amp;rft.aulast=Khanna+JM&amp;rft.au=Shah+G&amp;rft.au=Weiner+J&amp;rft.date=1992&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0091-3057%2892%2990110-2&amp;rft_id=info%3Apmid%2F1574525&amp;rft.issue=2&amp;rft.jtitle=Pharmacol.+Biochem.+Behav.&amp;rft.pages=355-60&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=41" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.who.int/medicines/areas/quality_safety/4.6ZopicloneCritReview.pdf">World Health Organisation - Assessment of Zopiclone</a></span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><span class="citation journal">Allan AM; Baier LD; Zhang X (1992). "Effects of lorazepam tolerance and withdrawal on GABAA receptor-operated chloride channels". <i>J. Pharmacol. Exp. Ther.</i> <b>261</b> (2): 395–402. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1374467">1374467</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Effects+of+lorazepam+tolerance+and+withdrawal+on+GABAA+receptor-operated+chloride+channels&amp;rft.au=Allan+AM&amp;rft.au=Baier+LD&amp;rft.aulast=Allan+AM&amp;rft.au=Zhang+X&amp;rft.date=1992&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F1374467&amp;rft.issue=2&amp;rft.jtitle=J.+Pharmacol.+Exp.+Ther.&amp;rft.pages=395-402&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=261" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><span class="citation journal">Rooke KC (1976). "The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice". <i>J Int Med Res</i> <b>4</b> (5): 355–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1177%2F030006057600400510">10.1177/030006057600400510</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18375">18375</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+use+of+flurazepam+%28dalmane%29+as+a+substitute+for+barbiturates+and+methaqualone%2Fdiphenhydramine+%28mandrax%29+in+general+practice&amp;rft.aulast=Rooke+KC&amp;rft.au=Rooke+KC&amp;rft.date=1976&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F030006057600400510&amp;rft_id=info%3Apmid%2F18375&amp;rft.issue=5&amp;rft.jtitle=J+Int+Med+Res&amp;rft.pages=355-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><span class="citation journal">Reddy DS; Rogawski MA (1 December 2000). <a rel="nofollow" class="external text" href="http://jpet.aspetjournals.org/cgi/content/full/295/3/1241">"Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself"</a>. <i>J Pharmacol Exp Ther</i> <b>295</b> (3): 1241–8. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11082461">11082461</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Chronic+treatment+with+the+neuroactive+steroid+ganaxolone+in+the+rat+induces+anticonvulsant+tolerance+to+diazepam+but+not+to+itself&amp;rft.aulast=Reddy+DS&amp;rft.au=Reddy+DS&amp;rft.au=Rogawski+MA&amp;rft.date=1+December+2000&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjpet.aspetjournals.org%2Fcgi%2Fcontent%2Ffull%2F295%2F3%2F1241&amp;rft_id=info%3Apmid%2F11082461&amp;rft.issue=3&amp;rft.jtitle=J+Pharmacol+Exp+Ther&amp;rft.pages=1241-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=295" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><span class="citation book">Martin D; Olsen RW (2000). <i>GABA in the nervous system: the view at fifty</i>. Philadelphia: Lippincott Williams Wilkins. p.&#160;211. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-7817-2267-5" title="Special:BookSources/0-7817-2267-5">0-7817-2267-5</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.aulast=Martin+D&amp;rft.au=Martin+D&amp;rft.au=Olsen+RW&amp;rft.btitle=GABA+in+the+nervous+system%3A+the+view+at+fifty&amp;rft.date=2000&amp;rft.genre=book&amp;rft.isbn=0-7817-2267-5&amp;rft.pages=211&amp;rft.place=Philadelphia&amp;rft.pub=Lippincott+Williams+Wilkins&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><span class="citation journal">Kroboth PD; McAuley JW (1997). "Progesterone: does it affect response to drug?". <i>Psychopharmacol Bull</i> <b>33</b> (2): 297–301. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9230647">9230647</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Progesterone%3A+does+it+affect+response+to+drug%3F&amp;rft.au=Kroboth+PD&amp;rft.aulast=Kroboth+PD&amp;rft.au=McAuley+JW&amp;rft.date=1997&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F9230647&amp;rft.issue=2&amp;rft.jtitle=Psychopharmacol+Bull&amp;rft.pages=297-301&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=33" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><span class="citation book">Smith SS (2004). <i>Neurosteroid effects in the central nervous system: the role of the GABA-A receptor</i>. Boca Raton, Fla.: CRC Press. pp.&#160;144–145. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8493-2392-8" title="Special:BookSources/978-0-8493-2392-8">978-0-8493-2392-8</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.aulast=Smith+SS&amp;rft.au=Smith+SS&amp;rft.btitle=Neurosteroid+effects+in+the+central+nervous+system%3A+the+role+of+the+GABA-A+receptor&amp;rft.date=2004&amp;rft.genre=book&amp;rft.isbn=978-0-8493-2392-8&amp;rft.pages=144-145&amp;rft.place=Boca+Raton%2C+Fla.&amp;rft.pub=CRC+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><span class="citation book">Rho JM; Sankar R; Cavazos JE (2004). <i>Epilepsy: scientific foundations of clinical practice</i>. New York: M. Dekker. p.&#160;336. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8247-5043-5" title="Special:BookSources/978-0-8247-5043-5">978-0-8247-5043-5</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.au=Cavazos+JE&amp;rft.aulast=Rho+JM&amp;rft.au=Rho+JM&amp;rft.au=Sankar+R&amp;rft.btitle=Epilepsy%3A+scientific+foundations+of+clinical+practice&amp;rft.date=2004&amp;rft.genre=book&amp;rft.isbn=978-0-8247-5043-5&amp;rft.pages=336&amp;rft.place=New+York&amp;rft.pub=M.+Dekker&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid7568184-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid7568184_34-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kaltschmidt C; Kaltschmidt B; Baeuerle PA (1995). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC40853">"Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons"</a>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <b>92</b> (21): 9618–22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1073%2Fpnas.92.21.9618">10.1073/pnas.92.21.9618</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC40853">40853</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7568184">7568184</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Stimulation+of+ionotropic+glutamate+receptors+activates+transcription+factor+NF-kappa+B+in+primary+neurons&amp;rft.au=Baeuerle+PA&amp;rft.au=Kaltschmidt+B&amp;rft.au=Kaltschmidt+C&amp;rft.aulast=Kaltschmidt+C&amp;rft.date=1995&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC40853&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.92.21.9618&amp;rft_id=info%3Apmc%2F40853&amp;rft_id=info%3Apmid%2F7568184&amp;rft.issue=21&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.pages=9618-22&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=92" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17684524-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17684524_35-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Humphries P; Pretorius E; Naudé H (2007). "Direct and indirect cellular effects of aspartame on the brain". <i>European Journal of Clinical Nutrition</i> <b>62</b> (4): 451–62. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.ejcn.1602866">10.1038/sj.ejcn.1602866</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0954-3007">0954-3007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17684524">17684524</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Direct+and+indirect+cellular+effects+of+aspartame+on+the+brain&amp;rft.au=Humphries+P&amp;rft.aulast=Humphries+P&amp;rft.au=Naud%C3%A9+H&amp;rft.au=Pretorius+E&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.ejcn.1602866&amp;rft_id=info%3Apmid%2F17684524&amp;rft.issn=0954-3007&amp;rft.issue=4&amp;rft.jtitle=European+Journal+of+Clinical+Nutrition&amp;rft.pages=451-62&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=62" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><span class="citation journal">Herlenius E, Langercrantz H (2004). "Development of neurotransmitter systems during critical periods". <i>Exp Neurol</i> <b>190</b>: 8–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.expneurol.2004.03.027">10.1016/j.expneurol.2004.03.027</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Development+of+neurotransmitter+systems+during+critical+periods&amp;rft.au=Herlenius+E%2C+Langercrantz+H&amp;rft.aulast=Herlenius+E%2C+Langercrantz+H&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.expneurol.2004.03.027&amp;rft.jtitle=Exp+Neurol&amp;rft.pages=8-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=190" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-url_synapses-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-url_synapses_37-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://thebrain.mcgill.ca/flash/a/a_01/a_01_m/a_01_m_ana/a_01_m_ana.html">"Synapses"</a>. <i>The Brain from Top to Bottom</i>. McGill University.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Synapses&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fthebrain.mcgill.ca%2Fflash%2Fa%2Fa_01%2Fa_01_m%2Fa_01_m_ana%2Fa_01_m_ana.html&amp;rft.jtitle=The+Brain+from+Top+to+Bottom&amp;rft.pub=McGill+University&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ashman-38"><span class="mw-cite-backlink">^ <a href="#cite_ref-ashman_38-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ashman_38-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-ashman_38-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-ashman_38-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-ashman_38-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-ashman_38-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation web">Professor Heather Ashton (2002). <a rel="nofollow" class="external text" href="http://benzo.org.uk/manual/index.htm">"Benzodiazepines: How They Work and How to Withdraw"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.aulast=Professor+Heather+Ashton&amp;rft.au=Professor+Heather+Ashton&amp;rft.btitle=Benzodiazepines%3A+How+They+Work+and+How+to+Withdraw&amp;rft.date=2002&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbenzo.org.uk%2Fmanual%2Findex.htm&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><span class="citation book">Brown TM; Stoudemire (1998). <a rel="nofollow" class="external text" href="http://books.google.com/books?id=K7kevbILCuQC&amp;pg=RA3-PA137&amp;lpg=RA3-PA137#PRA3-PA137,M1">"Chapter 7 Sedative-Hypnotics and Related Agents"</a>. <i>Psychiatric side effects of prescription and over-the-counter medications: recognition and management</i>. USA: American Psychiatric Press Inc. pp.&#160;132–133. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-88048-868-9" title="Special:BookSources/0-88048-868-9">0-88048-868-9</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Chapter+7+Sedative-Hypnotics+and+Related+Agents&amp;rft.au=Brown+TM&amp;rft.aulast=Brown+TM&amp;rft.au=Stoudemire&amp;rft.btitle=Psychiatric+side+effects+of+prescription+and+over-the-counter+medications%3A+recognition+and+management&amp;rft.date=1998&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DK7kevbILCuQC%26pg%3DRA3-PA137%26lpg%3DRA3-PA137%23PRA3-PA137%2CM1&amp;rft.isbn=0-88048-868-9&amp;rft.pages=132-133&amp;rft.place=USA&amp;rft.pub=American+Psychiatric+Press+Inc&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><span class="citation journal">Wichniak A; Brunner H; Ising M; Pedrosa Gil F; Holsboer F; Friess E (October 2004). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S0306453003002221">"Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression"</a>. <i>Psychoneuroendocrinology</i> <b>29</b> (9): 1101–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.psyneuen.2003.11.004">10.1016/j.psyneuen.2003.11.004</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15219633">15219633</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Impaired+hypothalamic-pituitary-adrenocortical+%28HPA%29+system+is+related+to+severity+of+benzodiazepine+withdrawal+in+patients+with+depression&amp;rft.au=Brunner+H&amp;rft.au=Friess+E&amp;rft.au=Holsboer+F&amp;rft.au=Ising+M&amp;rft.aulast=Wichniak+A&amp;rft.au=Pedrosa+Gil+F&amp;rft.au=Wichniak+A&amp;rft.date=October+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0306453003002221&amp;rft_id=info%3Adoi%2F10.1016%2Fj.psyneuen.2003.11.004&amp;rft_id=info%3Apmid%2F15219633&amp;rft.issue=9&amp;rft.jtitle=Psychoneuroendocrinology&amp;rft.pages=1101-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><span class="citation journal">Biggio G; Dazzi L; Biggio F et al. (December 2003). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S0924977X03001755">"Molecular mechanisms of tolerance to and withdrawal of GABA(A) receptor modulators"</a>. <i>Eur Neuropsychopharmacol</i> <b>13</b> (6): 411–23. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.euroneuro.2003.08.002">10.1016/j.euroneuro.2003.08.002</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14636957">14636957</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Molecular+mechanisms+of+tolerance+to+and+withdrawal+of+GABA%28A%29+receptor+modulators&amp;rft.au=Biggio+F&amp;rft.au=Biggio+G&amp;rft.au=Dazzi+L&amp;rft.aulast=Biggio+G&amp;rft.date=December+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0924977X03001755&amp;rft_id=info%3Adoi%2F10.1016%2Fj.euroneuro.2003.08.002&amp;rft_id=info%3Apmid%2F14636957&amp;rft.issue=6&amp;rft.jtitle=Eur+Neuropsychopharmacol&amp;rft.pages=411-23&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><span class="citation journal">Bateson AN (2002). "Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal". <i>Curr. Pharm. Des.</i> <b>8</b> (1): 5–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F1381612023396681">10.2174/1381612023396681</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11812247">11812247</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Basic+pharmacologic+mechanisms+involved+in+benzodiazepine+tolerance+and+withdrawal&amp;rft.au=Bateson+AN&amp;rft.aulast=Bateson+AN&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2174%2F1381612023396681&amp;rft_id=info%3Apmid%2F11812247&amp;rft.issue=1&amp;rft.jtitle=Curr.+Pharm.+Des.&amp;rft.pages=5-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><span class="citation journal">Follesa P; Cagetti E; Mancuso L et al. (August 2001). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S0169328X01001644">"Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists"</a>. <i>Brain Res. Mol. Brain Res.</i> <b>92</b> (1–2): 138–48. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0169-328X%2801%2900164-4">10.1016/S0169-328X(01)00164-4</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11483250">11483250</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Increase+in+expression+of+the+GABA%28A%29+receptor+alpha%284%29+subunit+gene+induced+by+withdrawal+of%2C+but+not+by+long-term+treatment+with%2C+benzodiazepine+full+or+partial+agonists&amp;rft.au=Cagetti+E&amp;rft.au=Follesa+P&amp;rft.aulast=Follesa+P&amp;rft.au=Mancuso+L&amp;rft.date=August+2001&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0169328X01001644&amp;rft_id=info%3Adoi%2F10.1016%2FS0169-328X%2801%2900164-4&amp;rft_id=info%3Apmid%2F11483250&amp;rft.issue=1%E2%80%932&amp;rft.jtitle=Brain+Res.+Mol.+Brain+Res.&amp;rft.pages=138-48&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=92" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-sbtp2-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-sbtp2_44-0">^</a></b></span> <span class="reference-text"><span class="citation book">Tyrer P; Silk KR, eds. (24 January 2008). <a rel="nofollow" class="external text" href="http://books.google.co.uk/books?id=HLPXELjTgdEC&amp;pg=PA402">"Treatment of sedative-hypnotic dependence"</a>. <a rel="nofollow" class="external text" href="http://books.google.com/?id=HLPXELjTgdEC"><i>Cambridge Textbook of Effective Treatments in Psychiatry</i></a> (1st ed.). Cambridge University Press. p.&#160;402. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-521-84228-0" title="Special:BookSources/978-0-521-84228-0">978-0-521-84228-0</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Treatment+of+sedative-hypnotic+dependence&amp;rft.btitle=Cambridge+Textbook+of+Effective+Treatments+in+Psychiatry&amp;rft.date=24+January+2008&amp;rft.edition=1st&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3DHLPXELjTgdEC&amp;rft.isbn=978-0-521-84228-0&amp;rft.pages=402&amp;rft.pub=Cambridge+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><span class="citation book">Karch SB (20 December 2006). <a rel="nofollow" class="external text" href="http://books.google.com/?id=F0mUte90ATUC"><i>Drug Abuse Handbook</i></a> (2nd ed.). United States of America: CRC Press. p.&#160;617. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8493-1690-6" title="Special:BookSources/978-0-8493-1690-6">978-0-8493-1690-6</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.au=Karch+SB&amp;rft.aulast=Karch+SB&amp;rft.btitle=Drug+Abuse+Handbook&amp;rft.date=20+December+2006&amp;rft.edition=2nd&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3DF0mUte90ATUC&amp;rft.isbn=978-0-8493-1690-6&amp;rft.pages=617&amp;rft.place=United+States+of+America&amp;rft.pub=CRC+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Committee_on_the_Review_of_Medicines_910.E2.80.932-46"><span class="mw-cite-backlink">^ <a href="#cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Committee_on_the_Review_of_Medicines_910.E2.80.932_46-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Committee on the Review of Medicines (March 29, 1980). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1601049">"Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines"</a>. <i>Br Med J</i> <b>280</b> (6218): 910–2. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1136%2Fbmj.280.6218.910">10.1136/bmj.280.6218.910</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1601049">1601049</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7388368">7388368</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Systematic+review+of+the+benzodiazepines.+Guidelines+for+data+sheets+on+diazepam%2C+chlordiazepoxide%2C+medazepam%2C+clorazepate%2C+lorazepam%2C+oxazepam%2C+temazepam%2C+triazolam%2C+nitrazepam%2C+and+flurazepam.+Committee+on+the+Review+of+Medicines&amp;rft.au=Committee+on+the+Review+of+Medicines&amp;rft.aulast=Committee+on+the+Review+of+Medicines&amp;rft.date=March+29%2C+1980&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1601049&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.280.6218.910&amp;rft_id=info%3Apmc%2F1601049&amp;rft_id=info%3Apmid%2F7388368&amp;rft.issue=6218&amp;rft.jtitle=Br+Med+J&amp;rft.pages=910-2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=280" class="Z3988"><span style="display:none;">&#160;</span></span></span>
<table class="cquote" role="presentation" style="margin:auto; border-collapse: collapse; border: none; background-color: transparent; width: auto;">
<tr>
<td style="width: 20px; vertical-align: top; border: none; color: #B2B7F2; font-size: 40px; font-family: 'Times New Roman', Times, serif; font-weight: bold; line-height: .6em; text-align: left; padding: 10px 10px;">“</td>
<td style="vertical-align: top; border: none; padding: 4px 10px;">The commitee concluded that, on the present available evidence, the true addiction potential of benzodiazepines was low. The number dependant on the benzodiazepines in the UK from 1960 to 1977 has been estimated to be 28 persons. This is equivalent to a dependance rate of 5-10 cases per millions patient months.</td>
<td style="width: 20px; vertical-align: bottom; border: none; color: #B2B7F2; font-size: 40px; font-family: 'Times New Roman', Times, serif; font-weight: bold; line-height: .6em; text-align: right; padding: 10px 10px;">”</td>
</tr>
</table>
</li>
<li id="cite_note-evidence_based_diagnosis_in_primary_care-47"><span class="mw-cite-backlink">^ <a href="#cite_ref-evidence_based_diagnosis_in_primary_care_47-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-evidence_based_diagnosis_in_primary_care_47-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-evidence_based_diagnosis_in_primary_care_47-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-evidence_based_diagnosis_in_primary_care_47-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-evidence_based_diagnosis_in_primary_care_47-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Polmear A (31 March 2008). <a rel="nofollow" class="external text" href="http://books.google.co.uk/books?id=LiXjoOQE-VkC&amp;pg=PA346"><i>Evidence-Based Diagnosis in Primary Care: Practical Solutions to Common Problems</i></a>. United Kingdom: Butterworth-Heinemann. pp.&#160;346–347. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-7506-4910-0" title="Special:BookSources/978-0-7506-4910-0">978-0-7506-4910-0</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.aulast=Polmear+A&amp;rft.au=Polmear+A&amp;rft.btitle=Evidence-Based+Diagnosis+in+Primary+Care%3A+Practical+Solutions+to+Common+Problems&amp;rft.date=31+March+2008&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbooks.google.co.uk%2Fbooks%3Fid%3DLiXjoOQE-VkC%26pg%3DPA346&amp;rft.isbn=978-0-7506-4910-0&amp;rft.pages=346-347&amp;rft.place=United+Kingdom&amp;rft.pub=Butterworth-Heinemann&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><span class="citation web"><a href="/wiki/ICD-10" title="ICD-10">ICD-10</a> (2007). <a rel="nofollow" class="external text" href="http://web.archive.org/web/20090727142809*/http://apps.who.int/classifications/apps/icd/icd10online/?gf10.htm+f13">"Chapter V - Mental and behavioural disorders (F00-F99) - Mental and behavioural disorders due to psychoactive substance use, 10-F19)"</a>. World Health Organisation. Archived from <a rel="nofollow" class="external text" href="http://apps.who.int/classifications/apps/icd/icd10online/?gf10.htm+f13">the original</a> on 2009-07-27.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.au=ICD-10&amp;rft.aulast=ICD-10&amp;rft.btitle=Chapter+V+-+Mental+and+behavioural+disorders+%28F00-F99%29+-+Mental+and+behavioural+disorders+due+to+psychoactive+substance+use%2C+10-F19%29&amp;rft.date=2007&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fapps.who.int%2Fclassifications%2Fapps%2Ficd%2Ficd10online%2F%3Fgf10.htm%2Bf13&amp;rft.pub=World+Health+Organisation&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><span class="citation journal">Madhusoodanan S; Bogunovic OJ (September 2004). "Safety of benzodiazepines in the geriatric population". <i>Expert Opin Drug Saf</i> <b>3</b> (5): 485–93. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1517%2F14740338.3.5.485">10.1517/14740338.3.5.485</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15335303">15335303</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Safety+of+benzodiazepines+in+the+geriatric+population&amp;rft.au=Bogunovic+OJ&amp;rft.aulast=Madhusoodanan+S&amp;rft.au=Madhusoodanan+S&amp;rft.date=September+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1517%2F14740338.3.5.485&amp;rft_id=info%3Apmid%2F15335303&amp;rft.issue=5&amp;rft.jtitle=Expert+Opin+Drug+Saf&amp;rft.pages=485-93&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><span class="citation journal">Baillargeon L; Landreville P; Verreault R; Beauchemin JP; Grégoire JP; Morin CM (November 2003). <a rel="nofollow" class="external text" href="http://eprints.ucl.ac.uk/6558/1/6558.pdf">"Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial"</a> <span style="font-size:85%;">(PDF)</span>. <i>CMAJ</i> <b>169</b> (10): 1015–20. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC236226">236226</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14609970">14609970</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Discontinuation+of+benzodiazepines+among+older+insomniac+adults+treated+with+cognitive-behavioural+therapy+combined+with+gradual+tapering%3A+a+randomized+trial&amp;rft.au=Baillargeon+L&amp;rft.au=Beauchemin+JP&amp;rft.au=Gr%C3%A9goire+JP&amp;rft.au=Landreville+P&amp;rft.aulast=Baillargeon+L&amp;rft.au=Morin+CM&amp;rft.au=Verreault+R&amp;rft.date=November+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Feprints.ucl.ac.uk%2F6558%2F1%2F6558.pdf&amp;rft_id=info%3Apmc%2F236226&amp;rft_id=info%3Apmid%2F14609970&amp;rft.issue=10&amp;rft.jtitle=CMAJ&amp;rft.pages=1015-20&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=169" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22572594-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22572594_51-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Casati A; Sedefov R; Pfeiffer-Gerschel T (2012). <a rel="nofollow" class="external text" href="http://content.karger.com/produktedb/produkte.asp?DOI=000337028&amp;typ=pdf">"Misuse of medicines in the European Union: a systematic review of the literature"</a> <span style="font-size:85%;">(PDF)</span>. <i>Eur Addict Res</i> <b>18</b> (5): 228–45. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1159%2F000337028">10.1159/000337028</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22572594">22572594</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Misuse+of+medicines+in+the+European+Union%3A+a+systematic+review+of+the+literature&amp;rft.au=Casati+A&amp;rft.aulast=Casati+A&amp;rft.au=Pfeiffer-Gerschel+T&amp;rft.au=Sedefov+R&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fcontent.karger.com%2Fproduktedb%2Fprodukte.asp%3FDOI%3D000337028%26typ%3Dpdf&amp;rft_id=info%3Adoi%2F10.1159%2F000337028&amp;rft_id=info%3Apmid%2F22572594&amp;rft.issue=5&amp;rft.jtitle=Eur+Addict+Res&amp;rft.pages=228-45&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-afr.2009-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-afr.2009_52-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Authier N; Balayssac D; Sautereau M; Zangarelli A; Courty P; Somogyi AA; Vennat B; Llorca PM; EschalierA (Nov 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". <i>Ann Pharm Fr</i> <b>67</b> (6): 408–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pharma.2009.07.001">10.1016/j.pharma.2009.07.001</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19900604">19900604</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+dependence%3A+focus+on+withdrawal+syndrome&amp;rft.au=Authier+N&amp;rft.au=Balayssac+D&amp;rft.au=Courty+P&amp;rft.au=EschalierA&amp;rft.aulast=Authier+N&amp;rft.au=Llorca+PM&amp;rft.au=Sautereau+M&amp;rft.au=Somogyi+AA&amp;rft.au=Vennat+B&amp;rft.au=Zangarelli+A&amp;rft.date=Nov+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharma.2009.07.001&amp;rft_id=info%3Apmid%2F19900604&amp;rft.issue=6&amp;rft.jtitle=Ann+Pharm+Fr&amp;rft.pages=408-13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=67" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><span class="citation book">Panus P; Katzung BG; Jobst EE; Tinsley S; Masters SB; Trevor AJ (November 2008). <a rel="nofollow" class="external text" href="http://books.google.co.uk/books?id=ijbNEiFbaTwC&amp;pg=PA182">"Sedative-hypnotic drugs"</a>. <a rel="nofollow" class="external text" href="http://books.google.com/?id=ijbNEiFbaTwC"><i>Pharmacology for the Physical Therapist</i></a> (1 ed.). McGraw-Hill Medical. p.&#160;192. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-146043-9" title="Special:BookSources/978-0-07-146043-9">978-0-07-146043-9</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Sedative-hypnotic+drugs&amp;rft.au=Jobst+EE&amp;rft.au=Katzung+BG&amp;rft.aulast=Panus+P&amp;rft.au=Masters+SB&amp;rft.au=Panus+P&amp;rft.au=Tinsley+S&amp;rft.au=Trevor+AJ&amp;rft.btitle=Pharmacology+for+the+Physical+Therapist&amp;rft.date=November+2008&amp;rft.edition=1&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3DijbNEiFbaTwC&amp;rft.isbn=978-0-07-146043-9&amp;rft.pages=192&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><span class="citation book">Tyrer P; Silk KR, eds. (24 January 2008). <a rel="nofollow" class="external text" href="http://books.google.com/?id=HLPXELjTgdEC"><i>Cambridge Textbook of Effective Treatments in Psychiatry</i></a> (1st ed.). Cambridge University Press. p.&#160;532. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-521-84228-0" title="Special:BookSources/978-0-521-84228-0">978-0-521-84228-0</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.btitle=Cambridge+Textbook+of+Effective+Treatments+in+Psychiatry&amp;rft.date=24+January+2008&amp;rft.edition=1st&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3DHLPXELjTgdEC&amp;rft.isbn=978-0-521-84228-0&amp;rft.pages=532&amp;rft.pub=Cambridge+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-LugoboniFaccini2011-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-LugoboniFaccini2011_55-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lugoboni F; Faccini M; Quaglio G; Casari R; Albiero A; Pajusco B (2011). "Agonist substitution for high-dose benzodiazepine-dependent patients: let us not forget the importance of flumazenil". <i>Addiction</i> <b>106</b> (4): 853–853. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1360-0443.2010.03327.x">10.1111/j.1360-0443.2010.03327.x</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0965-2140">0965-2140</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Agonist+substitution+for+high-dose+benzodiazepine-dependent+patients%3A+let+us+not+forget+the+importance+of+flumazenil&amp;rft.au=Albiero+A&amp;rft.au=Casari+R&amp;rft.au=Faccini+M&amp;rft.aulast=Lugoboni+F&amp;rft.au=Lugoboni+F&amp;rft.au=Pajusco+B&amp;rft.au=Quaglio+G&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1360-0443.2010.03327.x&amp;rft.issn=09652140&amp;rft.issue=4&amp;rft.jtitle=Addiction&amp;rft.pages=853-853&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-LugoboniLeone2012-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-LugoboniLeone2012_56-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lugoboni F; Leone R (2012). "What is stopping us from using Flumazenil?". <i>Addiction</i> <b>107</b> (7): 1359–1359. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1360-0443.2012.03851.x">10.1111/j.1360-0443.2012.03851.x</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0965-2140">0965-2140</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=What+is+stopping+us+from+using+Flumazenil%3F&amp;rft.aulast=Lugoboni+F&amp;rft.au=Leone+R&amp;rft.au=Lugoboni+F&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1360-0443.2012.03851.x&amp;rft.issn=09652140&amp;rft.issue=7&amp;rft.jtitle=Addiction&amp;rft.pages=1359-1359&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=107" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Savic1991-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-Savic1991_57-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Savic I (1991). "Feasibility of reversing benzodiazepine tolerance with flumazenil". <i>The Lancet</i> <b>337</b> (8734): 133–137. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0140-6736%2891%2990799-U">10.1016/0140-6736(91)90799-U</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0140-6736">0140-6736</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Feasibility+of+reversing+benzodiazepine+tolerance+with+flumazenil&amp;rft.aulast=Savic+I&amp;rft.au=Savic+I&amp;rft.date=1991&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0140-6736%2891%2990799-U&amp;rft.issn=01406736&amp;rft.issue=8734&amp;rft.jtitle=The+Lancet&amp;rft.pages=133-137&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=337" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-QuaglioPattaro2012-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-QuaglioPattaro2012_58-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Quaglio G; Pattaro C; Gerra G; Mathew S; Verbanck P; Des Jarlais DC; Lugoboni F (2012). "High dose benzodiazepine dependence: Description of 29 patients treated with flumazenil infusion and stabilised with clonazepam". <i>Psychiatry Research</i> <b>198</b> (3): 457–462. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.psychres.2012.02.008">10.1016/j.psychres.2012.02.008</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0165-1781">0165-1781</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22424905">22424905</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=High+dose+benzodiazepine+dependence%3A+Description+of+29+patients+treated+with+flumazenil+infusion+and+stabilised+with+clonazepam&amp;rft.au=Des+Jarlais+DC&amp;rft.au=Gerra+G&amp;rft.aulast=Quaglio+G&amp;rft.au=Lugoboni+F&amp;rft.au=Mathew+S&amp;rft.au=Pattaro+C&amp;rft.au=Quaglio+G&amp;rft.au=Verbanck+P&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.psychres.2012.02.008&amp;rft_id=info%3Apmid%2F22424905&amp;rft.issn=01651781&amp;rft.issue=3&amp;rft.jtitle=Psychiatry+Research&amp;rft.pages=457-462&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=198" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><span class="citation journal">Gerra G; Giucasto G; Zaimovic A; Fertonani G; Chittolini B; Avanzini P; Caccavari R (June 1996). "Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal". <i>International clinical psychopharmacology</i> <b>11</b> (2): 81–88. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2F00004850-199611020-00002">10.1097/00004850-199611020-00002</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8803645">8803645</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Intravenous+flumazenil+following+prolonged+exposure+to+lormetazepam+in+humans%3A+lack+of+precipitated+withdrawal&amp;rft.au=Avanzini+P&amp;rft.au=Caccavari+R&amp;rft.au=Chittolini+B&amp;rft.au=Fertonani+G&amp;rft.au=Gerra+G&amp;rft.au=Giucasto+G&amp;rft.aulast=Gerra+G&amp;rft.au=Zaimovic+A&amp;rft.date=June+1996&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2F00004850-199611020-00002&amp;rft_id=info%3Apmid%2F8803645&amp;rft.issue=2&amp;rft.jtitle=International+clinical+psychopharmacology&amp;rft.pages=81-88&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-GerraZaimovic2002-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-GerraZaimovic2002_60-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Gerra G; Zaimovic A; Giusti F; Moi G; Brewer C (2002). "Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study". <i>Addiction Biology</i> <b>7</b> (4): 385–395. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F1355621021000005973">10.1080/1355621021000005973</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/1355-6215">1355-6215</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14578014">14578014</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Intravenous+flumazenil+versus+oxazepam+tapering+in+the+treatment+of+benzodiazepine+withdrawal%3A+a+randomized%2C+placebo-controlled+study&amp;rft.au=Brewer+C&amp;rft.au=Gerra+G&amp;rft.au=Giusti+F&amp;rft.aulast=Gerra+G&amp;rft.au=Moi+G&amp;rft.au=Zaimovic+A&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1080%2F1355621021000005973&amp;rft_id=info%3Apmid%2F14578014&amp;rft.issn=1355-6215&amp;rft.issue=4&amp;rft.jtitle=Addiction+Biology&amp;rft.pages=385-395&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><span class="citation journal">Pericic D; Lazic J (August 2005). "Chronic treatment with flumazenil enhances binding sites for convulsants at recombinant alpha(1)beta(2)gamma(2S) GABA(A) receptors". <i>Biomedicine &amp; pharmacotherapy=Biomedecine &amp; pharmacotherapie</i> <b>59</b> (7): 408–414. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.biopha.2005.02.003">10.1016/j.biopha.2005.02.003</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16084060">16084060</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Chronic+treatment+with+flumazenil+enhances+binding+sites+for+convulsants+at+recombinant+alpha%281%29beta%282%29gamma%282S%29+GABA%28A%29+receptors&amp;rft.aulast=Pericic+D&amp;rft.au=Lazic+J&amp;rft.au=Pericic+D&amp;rft.date=August+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.biopha.2005.02.003&amp;rft_id=info%3Apmid%2F16084060&amp;rft.issue=7&amp;rft.jtitle=Biomedicine+%26+pharmacotherapy%3DBiomedecine+%26+pharmacotherapie&amp;rft.pages=408-414&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=59" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><span class="citation journal">Pericic D; Jembrek MJ; Strac DS; Lazic J (January 2005). "Enhancement of benzodiazepine binding sites following chronic treatment with flumazenil". <i><a href="/wiki/European_journal_of_pharmacology" title="European journal of pharmacology" class="mw-redirect">European journal of pharmacology</a></i> <b>507</b> (1–3): 7–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.ejphar.2004.10.057">10.1016/j.ejphar.2004.10.057</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15659288">15659288</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Enhancement+of+benzodiazepine+binding+sites+following+chronic+treatment+with+flumazenil&amp;rft.au=Jembrek+MJ&amp;rft.aulast=Pericic+D&amp;rft.au=Lazic+J&amp;rft.au=Pericic+D&amp;rft.au=Strac+DS&amp;rft.date=January+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ejphar.2004.10.057&amp;rft_id=info%3Apmid%2F15659288&amp;rft.issue=1%E2%80%933&amp;rft.jtitle=European+journal+of+pharmacology&amp;rft.pages=7-13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=507" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text"><span class="citation journal">Pericic D; Lazic J; Jembrek MJ; Strac DS (December 2004). "Chronic exposure of cells expressing recombinant GABAA receptors to benzodiazepine antagonist flumazenil enhances the maximum number of benzodiazepine binding sites". <i><a href="/wiki/Life_Sciences_(journal)" title="Life Sciences (journal)">Life sciences</a></i> <b>76</b> (3): 303–317. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.lfs.2004.07.013">10.1016/j.lfs.2004.07.013</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15531382">15531382</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Chronic+exposure+of+cells+expressing+recombinant+GABAA+receptors+to+benzodiazepine+antagonist+flumazenil+enhances+the+maximum+number+of+benzodiazepine+binding+sites&amp;rft.au=Jembrek+MJ&amp;rft.aulast=Pericic+D&amp;rft.au=Lazic+J&amp;rft.au=Pericic+D&amp;rft.au=Strac+DS&amp;rft.date=December+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.lfs.2004.07.013&amp;rft_id=info%3Apmid%2F15531382&amp;rft.issue=3&amp;rft.jtitle=Life+sciences&amp;rft.pages=303-317&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=76" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><span class="citation journal">Jembrek MJ; Strac DS; Vlainic J (July 2008). "The role of transcriptional and translational mechanisms in flumazenil-induced up-regulation of recombinant GABA(A) receptors". <i>Neuroscience research</i> <b>61</b> (3): 234–241. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.neures.2008.03.005">10.1016/j.neures.2008.03.005</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18453026">18453026</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+role+of+transcriptional+and+translational+mechanisms+in+flumazenil-induced+up-regulation+of+recombinant+GABA%28A%29+receptors&amp;rft.au=Jembrek+MJ&amp;rft.aulast=Jembrek+MJ&amp;rft.au=Strac+DS&amp;rft.au=Vlainic+J&amp;rft.date=July+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neures.2008.03.005&amp;rft_id=info%3Apmid%2F18453026&amp;rft.issue=3&amp;rft.jtitle=Neuroscience+research&amp;rft.pages=234-241&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><span class="citation journal">Saxon L; Borg S (August 2010). "Reduction of aggression during benzodiazepine withdrawal: effects of flumazenil". <i><a href="/wiki/Pharmacology,_biochemistry,_and_behavior" title="Pharmacology, biochemistry, and behavior" class="mw-redirect">Pharmacology, biochemistry, and behavior</a></i> <b>96</b> (2): 148–151. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.pbb.2010.04.023">10.1016/j.pbb.2010.04.023</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20451546">20451546</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Reduction+of+aggression+during+benzodiazepine+withdrawal%3A+effects+of+flumazenil&amp;rft.au=Borg+S&amp;rft.aulast=Saxon+L&amp;rft.au=Saxon+L&amp;rft.date=August+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pbb.2010.04.023&amp;rft_id=info%3Apmid%2F20451546&amp;rft.issue=2&amp;rft.jtitle=Pharmacology%2C+biochemistry%2C+and+behavior&amp;rft.pages=148-151&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=96" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-66">^</a></b></span> <span class="reference-text"><span class="citation journal">Morgan JD; Wright DJ; Chrystyn H (December 2002). <a rel="nofollow" class="external text" href="http://www.kluweronline.com/art.pdf?issn=0928-1231&amp;volume=24&amp;page=231">"Pharmacoeconomic evaluation of a patient education letter aimed at reducing long-term prescribing of benzodiazepines"</a> <span style="font-size:85%;">(PDF)</span>. <i>Pharm World Sci</i> <b>24</b> (6): 231–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1023%2FA%3A1021587209529">10.1023/A:1021587209529</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12512155">12512155</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Pharmacoeconomic+evaluation+of+a+patient+education+letter+aimed+at+reducing+long-term+prescribing+of+benzodiazepines&amp;rft.au=Chrystyn+H&amp;rft.aulast=Morgan+JD&amp;rft.au=Morgan+JD&amp;rft.au=Wright+DJ&amp;rft.date=December+2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.kluweronline.com%2Fart.pdf%3Fissn%3D0928-1231%26volume%3D24%26page%3D231&amp;rft_id=info%3Adoi%2F10.1023%2FA%3A1021587209529&amp;rft_id=info%3Apmid%2F12512155&amp;rft.issue=6&amp;rft.jtitle=Pharm+World+Sci&amp;rft.pages=231-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><span class="citation journal">Stewart R; Niessen WJ; Broer J; Snijders TA; Haaijer-Ruskamp FM; Meyboom-De Jong B (October 2007). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S0895-4356(07)00026-1">"General Practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application"</a>. <i>J Clin Epidemiol</i> <b>60</b> (10): 1076–84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.jclinepi.2006.11.024">10.1016/j.jclinepi.2006.11.024</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17884604">17884604</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=General+Practitioners+reduced+benzodiazepine+prescriptions+in+an+intervention+study%3A+a+multilevel+application&amp;rft.au=Broer+J&amp;rft.au=Haaijer-Ruskamp+FM&amp;rft.aulast=Stewart+R&amp;rft.au=Meyboom-De+Jong+B&amp;rft.au=Niessen+WJ&amp;rft.au=Snijders+TA&amp;rft.au=Stewart+R&amp;rft.date=October+2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0895-4356%2807%2900026-1&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jclinepi.2006.11.024&amp;rft_id=info%3Apmid%2F17884604&amp;rft.issue=10&amp;rft.jtitle=J+Clin+Epidemiol&amp;rft.pages=1076-84&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=60" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><span class="citation journal">Niessen WJ; Stewart RE; Broer J; Haaijer-Ruskamp FM (February 2005). "Vermindering van gebruik van benzodiazepinen door een brief van de eigen huisarts aan chronische gebruikers" [Reduction in the consumption of benzodiazepines due to a letter to chronic users from their own general practitioner]. <i>Ned Tijdschr Geneeskd</i> (in Dutch and Flemish) <b>149</b> (7): 356–61. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15751808">15751808</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Vermindering+van+gebruik+van+benzodiazepinen+door+een+brief+van+de+eigen+huisarts+aan+chronische+gebruikers&amp;rft.au=Broer+J&amp;rft.au=Haaijer-Ruskamp+FM&amp;rft.aulast=Niessen+WJ&amp;rft.au=Niessen+WJ&amp;rft.au=Stewart+RE&amp;rft.date=February+2005&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F15751808&amp;rft.issue=7&amp;rft.jtitle=Ned+Tijdschr+Geneeskd&amp;rft.pages=356-61&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=149" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-69">^</a></b></span> <span class="reference-text"><span class="citation journal">Westbury J; Jackson S; Gee P; Peterson G (Oct 2009). "An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project". <i>Int Psychogeriatr</i> <b>22</b> (1): 1–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1017%2FS1041610209991128">10.1017/S1041610209991128</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19814843">19814843</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=An+effective+approach+to+decrease+antipsychotic+and+benzodiazepine+use+in+nursing+homes%3A+the+RedUSe+project&amp;rft.au=Gee+P&amp;rft.au=Jackson+S&amp;rft.aulast=Westbury+J&amp;rft.au=Peterson+G&amp;rft.au=Westbury+J&amp;rft.date=Oct+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1017%2FS1041610209991128&amp;rft_id=info%3Apmid%2F19814843&amp;rft.issue=1&amp;rft.jtitle=Int+Psychogeriatr&amp;rft.pages=1-11&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text"><span class="citation journal">Morgan K; Dixon S; Mathers N; Thompson J; Tomeny M (February 2004). <a rel="nofollow" class="external text" href="http://www.hta.ac.uk/fullmono/mon808.pdf">"Psychological treatment for insomnia in the regulation of long-term hypnotic drug use"</a> <span style="font-size:85%;">(PDF)</span>. <i>Health Technol Assess</i> (National Institute for Health Research) <b>8</b> (8): 1–68. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3310%2Fhta8080">10.3310/hta8080</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14960254">14960254</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Psychological+treatment+for+insomnia+in+the+regulation+of+long-term+hypnotic+drug+use&amp;rft.au=Dixon+S&amp;rft.aulast=Morgan+K&amp;rft.au=Mathers+N&amp;rft.au=Morgan+K&amp;rft.au=Thompson+J&amp;rft.au=Tomeny+M&amp;rft.date=February+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.hta.ac.uk%2Ffullmono%2Fmon808.pdf&amp;rft_id=info%3Adoi%2F10.3310%2Fhta8080&amp;rft_id=info%3Apmid%2F14960254&amp;rft.issue=8&amp;rft.jtitle=Health+Technol+Assess&amp;rft.pages=1-68&amp;rft.pub=National+Institute+for+Health+Research&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-71">^</a></b></span> <span class="reference-text"><span class="citation journal">Baillargeon L; Landreville P; Verreault R; Beauchemin JP; Grégoire JP; Morin CM (November 2003). <a rel="nofollow" class="external text" href="http://www.cmaj.ca/cgi/content/full/169/10/1015">"Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial"</a>. <i>CMAJ</i> <b>169</b> (10): 1015–20. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC236226">236226</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14609970">14609970</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Discontinuation+of+benzodiazepines+among+older+insomniac+adults+treated+with+cognitive-behavioural+therapy+combined+with+gradual+tapering%3A+a+randomized+trial&amp;rft.au=Baillargeon+L&amp;rft.au=Beauchemin+JP&amp;rft.au=Gr%C3%A9goire+JP&amp;rft.au=Landreville+P&amp;rft.aulast=Baillargeon+L&amp;rft.au=Morin+CM&amp;rft.au=Verreault+R&amp;rft.date=November+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cmaj.ca%2Fcgi%2Fcontent%2Ffull%2F169%2F10%2F1015&amp;rft_id=info%3Apmc%2F236226&amp;rft_id=info%3Apmid%2F14609970&amp;rft.issue=10&amp;rft.jtitle=CMAJ&amp;rft.pages=1015-20&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=169" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><span class="citation journal">Gosselin P; Ladouceur R; Morin CM; Dugas MJ; Baillargeon L (October 2006). "Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy". <i>J Consult Clin Psychol</i> <b>74</b> (5): 908–19. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1037%2F0022-006X.74.5.908">10.1037/0022-006X.74.5.908</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17032095">17032095</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+discontinuation+among+adults+with+GAD%3A+A+randomized+trial+of+cognitive-behavioral+therapy&amp;rft.au=Baillargeon+L&amp;rft.au=Dugas+MJ&amp;rft.au=Gosselin+P&amp;rft.au=Ladouceur+R&amp;rft.aulast=Gosselin+P&amp;rft.au=Morin+CM&amp;rft.date=October+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1037%2F0022-006X.74.5.908&amp;rft_id=info%3Apmid%2F17032095&amp;rft.issue=5&amp;rft.jtitle=J+Consult+Clin+Psychol&amp;rft.pages=908-19&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=74" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><span class="citation web">Gandy A; Widdup J; Gupta R; Shend'ge E; Popat A (11–15 May 2009). <a rel="nofollow" class="external text" href="http://docs.google.com/viewer?a=v&amp;q=cache:EMNQqEUpOF0J:www.gmc-uk.org/static/documents/content/Mene_PUBLISHABLE_minutes_11-15_May_09.pdf+%22general+medical+council%22+temazepam+benzodiazepine+withdrawal&amp;hl=en&amp;gl=uk&amp;pid=bl&amp;srcid=ADGEESgoIZFG59N3ovC1CWfXyxOOlcqxW-GX0yqEKIUyCBT1VLaKgAyVo5eYB4Ou2yg0nWGBvvbSqcccbyuNq3WD144I3p5sGX61Mwt-aSkai7xqxsFWAHflz1e7_cYxLc3YyAGb48U5&amp;sig=AHIEtbT01eLAVNmJ3NsFXdAr_NuT43hltw">"Fitness to Practice Panel 11–15 May 2009"</a> <span style="font-size:85%;">(PDF)</span>. United Kingdom: gmc-uk. Archived from <a rel="nofollow" class="external text" href="http://www.gmc-uk.org/static/documents/content/Mene_PUBLISHABLE_minutes_11-15_May_09.pdf">the original</a> <span style="font-size:85%;">(PDF)</span> on 2009.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.au=Gandy+A&amp;rft.au=Gupta+R&amp;rft.aulast=Gandy+A&amp;rft.au=Popat+A&amp;rft.au=Shend%27ge+E&amp;rft.au=Widdup+J&amp;rft.btitle=Fitness+to+Practice+Panel+11%E2%80%9315+May+2009&amp;rft.date=11-15+May+2009&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.gmc-uk.org%2Fstatic%2Fdocuments%2Fcontent%2FMene_PUBLISHABLE_minutes_11-15_May_09.pdf&amp;rft.place=United+Kingdom&amp;rft.pub=gmc-uk&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment">Cite uses deprecated parameter <code style="color:inherit; border:inherit; padding:inherit;">|month=</code> (<a href="/wiki/Help:CS1_errors#deprecated_params" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><span class="citation book">Ashton CH (1997). <a rel="nofollow" class="external text" href="http://www.benzo.org.uk/bzdep.htm">"Benzodiazepine Dependency"</a>. In Baum A; Newman S; Weinman J; West R; McManus C. <i>Cambridge Handbook of Psychology &amp; Medicine</i>. England: Cambridge University Press. pp.&#160;376–80.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+Dependency&amp;rft.au=Ashton+CH&amp;rft.aulast=Ashton+CH&amp;rft.btitle=Cambridge+Handbook+of+Psychology+%26+Medicine&amp;rft.date=1997&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.benzo.org.uk%2Fbzdep.htm&amp;rft.pages=376-80&amp;rft.place=England&amp;rft.pub=Cambridge+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18041658-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18041658_75-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Anthierens S; Habraken H; Petrovic M; Christiaens T (December 2007). <a rel="nofollow" class="external text" href="http://pdfserve.informaworld.com/491348__783865453.pdf">"The lesser evil? Initiating a benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives"</a> <span style="font-size:85%;">(PDF)</span>. <i>Scand J Prim Health Care</i> <b>25</b> (4): 214–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F02813430701726335">10.1080/02813430701726335</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3379762">3379762</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18041658">18041658</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+lesser+evil%3F+Initiating+a+benzodiazepine+prescription+in+general+practice%3A+a+qualitative+study+on+GPs%27+perspectives&amp;rft.au=Anthierens+S&amp;rft.au=Christiaens+T&amp;rft.au=Habraken+H&amp;rft.aulast=Anthierens+S&amp;rft.au=Petrovic+M&amp;rft.date=December+2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpdfserve.informaworld.com%2F491348__783865453.pdf&amp;rft_id=info%3Adoi%2F10.1080%2F02813430701726335&amp;rft_id=info%3Apmc%2F3379762&amp;rft_id=info%3Apmid%2F18041658&amp;rft.issue=4&amp;rft.jtitle=Scand+J+Prim+Health+Care&amp;rft.pages=214-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=25" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><span class="citation journal">Granados Menéndez MI; Salinero Fort MA; Palomo Ancillo M; Aliaga Gutiérrez L; García Escalonilla C; Ortega Orcos R (2006). <a rel="nofollow" class="external text" href="http://www.elsevier.es/revistas/0212-6567/38/159">"Adecuacion del uso de las benzodiacepinas zolpidem y zopiclona en problemas atendidos en atencion primaria" [Appropriate use of benzodiazepines zolpidem and zopiclone in diseases attended in primary care]</a>. <i>Aten Primaria</i> (in Spanish) <b>38</b> (3): 159–64. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1157%2F13090980">10.1157/13090980</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16945275">16945275</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Adecuacion+del+uso+de+las+benzodiacepinas+zolpidem+y+zopiclona+en+problemas+atendidos+en+atencion+primaria&amp;rft.au=Aliaga+Guti%C3%A9rrez+L&amp;rft.au=Garc%C3%ADa+Escalonilla+C&amp;rft.au=Granados+Men%C3%A9ndez+MI&amp;rft.aulast=Granados+Men%C3%A9ndez+MI&amp;rft.au=Ortega+Orcos+R&amp;rft.au=Palomo+Ancillo+M&amp;rft.au=Salinero+Fort+MA&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.elsevier.es%2Frevistas%2F0212-6567%2F38%2F159&amp;rft_id=info%3Adoi%2F10.1157%2F13090980&amp;rft_id=info%3Apmid%2F16945275&amp;rft.issue=3&amp;rft.jtitle=Aten+Primaria&amp;rft.pages=159-64&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=38" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text"><span class="citation journal">Barthelmé B; Poirot Y (November 2008). "Niveau d'anxiete et de dependance des primoconsommants d'anxiolytiques: une etude de psychometrie" [Anxiety level and addiction to first-time prescriptions of anxiolytics: a psychometric study]. <i>Presse Med [Medical Press]</i> (in French) <b>37</b> (11): 1555–60. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.lpm.2007.10.019">10.1016/j.lpm.2007.10.019</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18502091">18502091</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Niveau+d%27anxiete+et+de+dependance+des+primoconsommants+d%27anxiolytiques%3A+une+etude+de+psychometrie&amp;rft.au=Barthelm%C3%A9+B&amp;rft.aulast=Barthelm%C3%A9+B&amp;rft.au=Poirot+Y&amp;rft.date=November+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.lpm.2007.10.019&amp;rft_id=info%3Apmid%2F18502091&amp;rft.issue=11&amp;rft.jtitle=Presse+Med+%5BMedical+Press%5D&amp;rft.pages=1555-60&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=37" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><span class="citation journal">Fruensgaard K (February 1976). "Withdrawal psychosis: a study of 30 consecutive cases". <i>Acta Psychiatr Scand</i> <b>53</b> (2): 105–18. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1600-0447.1976.tb00065.x">10.1111/j.1600-0447.1976.tb00065.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3091">3091</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Withdrawal+psychosis%3A+a+study+of+30+consecutive+cases&amp;rft.au=Fruensgaard+K&amp;rft.aulast=Fruensgaard+K&amp;rft.date=February+1976&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1600-0447.1976.tb00065.x&amp;rft_id=info%3Apmid%2F3091&amp;rft.issue=2&amp;rft.jtitle=Acta+Psychiatr+Scand&amp;rft.pages=105-18&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=53" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><span class="citation journal">Lader M (1991). "History of benzodiazepine dependence". <i>Journal of substance abuse treatment</i> <b>8</b> (1–2): 53–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0740-5472%2891%2990027-8">10.1016/0740-5472(91)90027-8</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1675692">1675692</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=History+of+benzodiazepine+dependence&amp;rft.au=Lader+M&amp;rft.aulast=Lader+M&amp;rft.date=1991&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0740-5472%2891%2990027-8&amp;rft_id=info%3Apmid%2F1675692&amp;rft.issue=1%E2%80%932&amp;rft.jtitle=Journal+of+substance+abuse+treatment&amp;rft.pages=53-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><span class="citation journal">Lucki I; Kucharik RF (1990). "Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam". <i>Psychopharmacology</i> <b>102</b> (3): 350–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2FBF02244103">10.1007/BF02244103</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1979180">1979180</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Increased+sensitivity+to+benzodiazepine+antagonists+in+rats+following+chronic+treatment+with+a+low+dose+of+diazepam&amp;rft.au=Kucharik+RF&amp;rft.aulast=Lucki+I&amp;rft.au=Lucki+I&amp;rft.date=1990&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2FBF02244103&amp;rft_id=info%3Apmid%2F1979180&amp;rft.issue=3&amp;rft.jtitle=Psychopharmacology&amp;rft.pages=350-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=102" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text"><span class="citation journal">Rickels K; Case WG; Schweizer EE; Swenson C; Fridman RB (1986). "Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients". <i>Psychopharmacology bulletin</i> <b>22</b> (2): 407–15. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2877472">2877472</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Low-dose+dependence+in+chronic+benzodiazepine+users%3A+a+preliminary+report+on+119+patients&amp;rft.au=Case+WG&amp;rft.au=Fridman+RB&amp;rft.aulast=Rickels+K&amp;rft.au=Rickels+K&amp;rft.au=Schweizer+EE&amp;rft.au=Swenson+C&amp;rft.date=1986&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F2877472&amp;rft.issue=2&amp;rft.jtitle=Psychopharmacology+bulletin&amp;rft.pages=407-15&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-82">^</a></b></span> <span class="reference-text"><span class="citation journal">Lader M (December 1987). "Long-term anxiolytic therapy: the issue of drug withdrawal". <i>The Journal of clinical psychiatry</i> <b>48</b>: 12–6. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2891684">2891684</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Long-term+anxiolytic+therapy%3A+the+issue+of+drug+withdrawal&amp;rft.au=Lader+M&amp;rft.aulast=Lader+M&amp;rft.date=December+1987&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F2891684&amp;rft.jtitle=The+Journal+of+clinical+psychiatry&amp;rft.pages=12-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=48" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><span class="citation journal">Miura S; Murasaki M (March 1992). "The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives)". <i>Progress in neuro-psychopharmacology &amp; biological psychiatry</i> <b>16</b> (6): 833–45. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0278-5846%2892%2990103-L">10.1016/0278-5846(92)90103-L</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1355301">1355301</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=The+future+of+5-HT1A+receptor+agonists.+%28Aryl-piperazine+derivatives%29&amp;rft.aulast=Miura+S&amp;rft.au=Miura+S&amp;rft.au=Murasaki+M&amp;rft.date=March+1992&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0278-5846%2892%2990103-L&amp;rft_id=info%3Apmid%2F1355301&amp;rft.issue=6&amp;rft.jtitle=Progress+in+neuro-psychopharmacology+%26+biological+psychiatry&amp;rft.pages=833-45&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><span class="citation journal">Meier PJ; Ziegler WH; Neftel K (March 19, 1988). "Benzodiazepine--Praxis und Probleme ihrer Anwendung" [Benzodiazepine--practice and problems of its use]. <i>Schweizerische medizinische Wochenschrift [Swiss medical weekly]</i> <b>118</b> (11): 381–92. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3287602">3287602</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine--Praxis+und+Probleme+ihrer+Anwendung&amp;rft.aulast=Meier+PJ&amp;rft.au=Meier+PJ&amp;rft.au=Neftel+K&amp;rft.au=Ziegler+WH&amp;rft.date=March+19%2C+1988&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3287602&amp;rft.issue=11&amp;rft.jtitle=Schweizerische+medizinische+Wochenschrift+%5BSwiss+medical+weekly%5D&amp;rft.pages=381-92&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=118" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22413490-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22413490_85-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Tsuji K; Tajima O (January 2012). "[Anxiolytic]". <i>Nippon Rinsho</i> (in Japanese) <b>70</b> (1): 42–6. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22413490">22413490</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=%5BAnxiolytic%5D&amp;rft.aulast=Tsuji+K&amp;rft.au=Tajima+O&amp;rft.au=Tsuji+K&amp;rft.date=January+2012&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F22413490&amp;rft.issue=1&amp;rft.jtitle=Nippon+Rinsho&amp;rft.pages=42-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=70" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-86">^</a></b></span> <span class="reference-text"><span class="citation journal">Linden M; Bär T; Geiselmann B (May 1998). "Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions". <i>Psychological Medicine</i> <b>28</b> (3): 721–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1017%2FS0033291798006734">10.1017/S0033291798006734</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9626728">9626728</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Patient+treatment+insistence+and+medication+craving+in+long-term+low-dosage+benzodiazepine+prescriptions&amp;rft.au=B%C3%A4r+T&amp;rft.au=Geiselmann+B&amp;rft.aulast=Linden+M&amp;rft.au=Linden+M&amp;rft.date=May+1998&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1017%2FS0033291798006734&amp;rft_id=info%3Apmid%2F9626728&amp;rft.issue=3&amp;rft.jtitle=Psychological+Medicine&amp;rft.pages=721-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=28" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-87">^</a></b></span> <span class="reference-text"><span class="citation journal">Tyrer P (1993). "Benzodiazepine dependence: a shadowy diagnosis". <i>Biochemical Society Symposia</i> <b>59</b>: 107–19. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7910738">7910738</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepine+dependence%3A+a+shadowy+diagnosis&amp;rft.aulast=Tyrer+P&amp;rft.au=Tyrer+P&amp;rft.date=1993&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F7910738&amp;rft.jtitle=Biochemical+Society+Symposia&amp;rft.pages=107-19&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=59" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-88"><span class="mw-cite-backlink"><b><a href="#cite_ref-88">^</a></b></span> <span class="reference-text"><span class="citation book">Karch SB (20 December 2006). <a rel="nofollow" class="external text" href="http://books.google.com/?id=F0mUte90ATUC"><i>Drug Abuse Handbook</i></a> (2nd ed.). USA: CRC Press. p.&#160;35. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8493-1690-6" title="Special:BookSources/978-0-8493-1690-6">978-0-8493-1690-6</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.au=Karch+SB&amp;rft.aulast=Karch+SB&amp;rft.btitle=Drug+Abuse+Handbook&amp;rft.date=20+December+2006&amp;rft.edition=2nd&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbooks.google.com%2F%3Fid%3DF0mUte90ATUC&amp;rft.isbn=978-0-8493-1690-6&amp;rft.pages=35&amp;rft.place=USA&amp;rft.pub=CRC+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><span class="citation journal">Dièye AM; Sy AN; Sy GY et al. (2007). "Prescription des benzodiazepines par les medecins generalistes du prive a Dakar: Enquete sur les connaissances et les attitudes" [Prescription of benzodiazepines by general practitioners in the private sector of Dakar: survey on knowledge and attitudes]. <i>Therapie [Therapy]</i> (in French) <b>62</b> (2): 163–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2515%2Ftherapie%3A2007018">10.2515/therapie:2007018</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17582318">17582318</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Prescription+des+benzodiazepines+par+les+medecins+generalistes+du+prive+a+Dakar%3A+Enquete+sur+les+connaissances+et+les+attitudes&amp;rft.au=Di%C3%A8ye+AM&amp;rft.aulast=Di%C3%A8ye+AM&amp;rft.au=Sy+AN&amp;rft.au=Sy+GY&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2515%2Ftherapie%3A2007018&amp;rft_id=info%3Apmid%2F17582318&amp;rft.issue=2&amp;rft.jtitle=Therapie+%5BTherapy%5D&amp;rft.pages=163-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=62" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-90">^</a></b></span> <span class="reference-text"><span class="citation journal">Dièye AM; Sylla M; Ndiaye A; Ndiaye M; Sy GY; Faye B (June 2006). <a rel="nofollow" class="external text" href="http://www3.interscience.wiley.com/journal/118553133/abstract">"Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists"</a>. <i>Fundam Clin Pharmacol</i> <b>20</b> (3): 235–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1472-8206.2006.00400.x">10.1111/j.1472-8206.2006.00400.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16671957">16671957</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Benzodiazepines+prescription+in+Dakar%3A+a+study+about+prescribing+habits+and+knowledge+in+general+practitioners%2C+neurologists+and+psychiatrists&amp;rft.au=Di%C3%A8ye+AM&amp;rft.au=Faye+B&amp;rft.aulast=Di%C3%A8ye+AM&amp;rft.au=Ndiaye+A&amp;rft.au=Ndiaye+M&amp;rft.au=Sy+GY&amp;rft.au=Sylla+M&amp;rft.date=June+2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww3.interscience.wiley.com%2Fjournal%2F118553133%2Fabstract&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1472-8206.2006.00400.x&amp;rft_id=info%3Apmid%2F16671957&amp;rft.issue=3&amp;rft.jtitle=Fundam+Clin+Pharmacol&amp;rft.pages=235-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-91">^</a></b></span> <span class="reference-text"><span class="citation journal">Woody GE; Mc Lellan AT; O'Brien CP (1979). "Development of psychiatric illness in drug abusers. Possible role of drug preference". <i><a href="/wiki/The_New_England_Journal_of_Medicine" title="The New England Journal of Medicine">The New England Journal of Medicine</a></i> <b>301</b> (24): 1310–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM197912133012403">10.1056/NEJM197912133012403</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/41182">41182</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Development+of+psychiatric+illness+in+drug+abusers.+Possible+role+of+drug+preference&amp;rft.aulast=Woody+GE&amp;rft.au=Mc+Lellan+AT&amp;rft.au=O%27Brien+CP&amp;rft.au=Woody+GE&amp;rft.date=1979&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM197912133012403&amp;rft_id=info%3Apmid%2F41182&amp;rft.issue=24&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.pages=1310-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=301" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-92">^</a></b></span> <span class="reference-text"><span class="citation journal">Sheehan MF; Sheehan DV; Torres A; Coppola A; Francis E (1991). "Snorting benzodiazepines". <i>Am J Drug Alcohol Abuse</i> <b>17</b> (4): 457–68. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.3109%2F00952999109001605">10.3109/00952999109001605</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1684083">1684083</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Snorting+benzodiazepines&amp;rft.au=Coppola+A&amp;rft.au=Francis+E&amp;rft.aulast=Sheehan+MF&amp;rft.au=Sheehan+DV&amp;rft.au=Sheehan+MF&amp;rft.au=Torres+A&amp;rft.date=1991&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3109%2F00952999109001605&amp;rft_id=info%3Apmid%2F1684083&amp;rft.issue=4&amp;rft.jtitle=Am+J+Drug+Alcohol+Abuse&amp;rft.pages=457-68&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-93">^</a></b></span> <span class="reference-text"><span class="citation journal">Wetterling T; Backhaus J; Junghanns K (September 2002). "Sucht im Alter Ein unterschätztes Problem in der klinischen Versorgung älterer Menschen?" [Addiction in the elderly - an underestimated diagnosis in clinical practice?]. <i>Nervenarzt</i> (in German) <b>73</b> (9): 861–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs00115-002-1359-3">10.1007/s00115-002-1359-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12215877">12215877</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABenzodiazepine+dependence&amp;rft.atitle=Sucht+im+Alter+Ein+untersch%C3%A4tztes+Problem+in+der+klinischen+Versorgung+%C3%A4lterer+Menschen%3F&amp;rft.au=Backhaus+J&amp;rft.au=Junghanns+K&amp;rft.aulast=Wetterling+T&amp;rft.au=Wetterling+T&amp;rft.date=September+2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs00115-002-1359-3&amp;rft_id=info%3Apmid%2F12215877&amp;rft.issue=9&amp;rft.jtitle=Nervenarzt&amp;rft.pages=861-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=73" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit&amp;section=25" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a rel="nofollow" class="external text" href="http://www.benzo.org.uk/manual/">Benzodiazepines: How they work and how to withdraw by Professor Heather Ashton</a></li>
<li><a rel="nofollow" class="external text" href="https://www.dmoz.org/Health/Mental_Health/Disorders/Substance_Related/Support_Groups/">Benzodiazepine dependence</a> at <a href="/wiki/DMOZ" title="DMOZ">DMOZ</a></li>
</ul>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Psychoactive_substance_use" title="Template:Psychoactive substance use"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Psychoactive_substance_use" title="Template talk:Psychoactive substance use"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Psychoactive_substance_use&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Psychoactive_drug" title="Psychoactive drug">Psychoactive</a> <a href="/wiki/Substance-related_disorder" title="Substance-related disorder">substance-related disorder</a> (<a href="/wiki/ICD-10_Chapter_V:_Mental_and_behavioural_disorders#.28F10.E2.80.93F19.29_Mental_and_behavioural_disorders_due_to_psychoactive_substance_use" title="ICD-10 Chapter V: Mental and behavioural disorders">F10–F19</a>, <a href="/wiki/List_of_ICD-9_codes_290%E2%80%93319:_mental_disorders#Psychoactive_substance" title="List of ICD-9 codes 290–319: mental disorders">291–292; 303–305</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">General</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Substance-related_disorder#Substance-induced_disorders" title="Substance-related disorder">SID</a>
<ul>
<li><a href="/wiki/Substance_intoxication" title="Substance intoxication">Substance intoxication</a> / <a href="/wiki/Drug_overdose" title="Drug overdose">Drug overdose</a></li>
<li><a href="/wiki/Drug_withdrawal" title="Drug withdrawal">Withdrawal</a></li>
<li><a href="/wiki/Substance-induced_psychosis" title="Substance-induced psychosis">Substance-induced psychosis</a></li>
</ul>
</li>
<li><a href="/wiki/Substance_use_disorder" title="Substance use disorder">SUD</a>
<ul>
<li><a href="/wiki/Substance_abuse" title="Substance abuse">Substance abuse</a></li>
<li><a href="/wiki/Physical_dependence" title="Physical dependence">Physical dependence</a> / <a href="/wiki/Substance_dependence" title="Substance dependence">Substance dependence</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Ethanol" title="Ethanol">Alcohol</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;">SID</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;">Diseases</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;">Neurological<br />
disorders</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcoholic_hallucinosis" title="Alcoholic hallucinosis">Alcoholic hallucinosis</a></li>
<li><a href="/wiki/Alcohol_withdrawal_syndrome" title="Alcohol withdrawal syndrome">Alcohol withdrawal</a></li>
<li><a href="/wiki/Fetal_alcohol_spectrum_disorder" title="Fetal alcohol spectrum disorder">Fetal alcohol spectrum disorder</a> (FASD)</li>
<li><a href="/wiki/Fetal_alcohol_syndrome" title="Fetal alcohol syndrome" class="mw-redirect">Fetal alcohol syndrome</a> (FAS)</li>
<li><a href="/wiki/Korsakoff%27s_syndrome" title="Korsakoff's syndrome" class="mw-redirect">Korsakoff's syndrome</a></li>
<li><a href="/wiki/Wernicke%E2%80%93Korsakoff_syndrome" title="Wernicke–Korsakoff syndrome">Wernicke–Korsakoff syndrome</a></li>
<li><a href="/wiki/Wernicke%27s_encephalopathy" title="Wernicke's encephalopathy">Wernicke's encephalopathy</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;">Digestive<br />
system</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcoholic_hepatitis" title="Alcoholic hepatitis">Alcoholic hepatitis</a></li>
<li><a href="/wiki/Alcoholic_liver_disease" title="Alcoholic liver disease">Alcoholic liver disease</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;">Nervous<br />
system</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcohol-related_dementia" title="Alcohol-related dementia">Alcohol-related dementia</a></li>
<li><a href="/wiki/Alcoholic_hallucinosis" title="Alcoholic hallucinosis">Alcoholic hallucinosis</a></li>
<li><a href="/wiki/Hangover" title="Hangover">Hangover</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;"><a href="/wiki/Alcohol_and_cardiovascular_disease" title="Alcohol and cardiovascular disease">Cardiovascular<br />
system</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcoholic_cardiomyopathy" title="Alcoholic cardiomyopathy">Alcoholic cardiomyopathy</a></li>
<li><a href="/wiki/Alcohol_flush_reaction" title="Alcohol flush reaction">Alcohol flush reaction</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0;padding-right:0;">
<div style="padding:0em 0.75em;">SUD</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcoholism" title="Alcoholism">Alcoholism</a></li>
<li><a href="/wiki/Alcohol_dependence" title="Alcohol dependence">Alcohol dependence</a></li>
<li><a href="/wiki/Alcohol_abuse" title="Alcohol abuse">Alcohol abuse</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Opioid" title="Opioid">Opioids</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>SID
<ul>
<li><a href="/wiki/Opioid_overdose" title="Opioid overdose">Opioid overdose</a></li>
</ul>
</li>
<li>SUD
<ul>
<li><a href="/wiki/Opioid_dependence" title="Opioid dependence" class="mw-redirect">Opioid dependence</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Caffeine" title="Caffeine">Caffeine</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>SID
<ul>
<li><a href="/wiki/Effect_of_caffeine_on_memory" title="Effect of caffeine on memory">Effect of caffeine on memory</a></li>
<li><a href="/wiki/Caffeine-induced_sleep_disorder" title="Caffeine-induced sleep disorder">Caffeine-induced sleep disorder</a></li>
</ul>
</li>
<li>SUD
<ul>
<li><a href="/wiki/Caffeine_addiction" title="Caffeine addiction" class="mw-redirect">Caffeine addiction</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cannabis_(drug)" title="Cannabis (drug)">Cannabis</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>SID
<ul>
<li><a href="/wiki/Effects_of_cannabis" title="Effects of cannabis">Effects of cannabis</a></li>
<li><a href="/wiki/Long-term_effects_of_cannabis" title="Long-term effects of cannabis">Long-term effects of cannabis</a></li>
</ul>
</li>
<li>SUD
<ul>
<li><a href="/wiki/Cannabis_dependence" title="Cannabis dependence">Cannabis dependence</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Sedative" title="Sedative">Sedative</a> /<br />
<a href="/wiki/Hypnotic" title="Hypnotic">hypnotic</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Benzodiazepine" title="Benzodiazepine">benzodiazepine</a>:</i> SID
<ul>
<li><a href="/wiki/Benzodiazepine_overdose" title="Benzodiazepine overdose">Benzodiazepine overdose</a></li>
<li><a href="/wiki/Benzodiazepine_withdrawal_syndrome" title="Benzodiazepine withdrawal syndrome">Benzodiazepine withdrawal</a></li>
</ul>
</li>
<li>SUD
<ul>
<li><a href="/wiki/Benzodiazepine_misuse" title="Benzodiazepine misuse">Benzodiazepine misuse</a></li>
<li><strong class="selflink">Benzodiazepine dependence</strong></li>
</ul>
</li>
<li><i><a href="/wiki/Barbiturate" title="Barbiturate">barbiturate</a>:</i> SID
<ul>
<li><a href="/wiki/Barbiturate_overdose" title="Barbiturate overdose">Barbiturate overdose</a></li>
</ul>
</li>
<li>SUD
<ul>
<li><a href="/wiki/Barbiturate_dependence" title="Barbiturate dependence">Barbiturate dependence</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cocaine" title="Cocaine">Cocaine</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>SID
<ul>
<li><a href="/wiki/Cocaine_intoxication" title="Cocaine intoxication">Cocaine intoxication</a></li>
</ul>
</li>
<li>SUD
<ul>
<li><a href="/wiki/Cocaine_dependence" title="Cocaine dependence">Cocaine dependence</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Stimulant" title="Stimulant">Stimulants</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>SID
<ul>
<li><a href="/wiki/Stimulant_psychosis" title="Stimulant psychosis">Stimulant psychosis</a></li>
</ul>
</li>
<li>SUD
<ul>
<li><a href="/wiki/Amphetamine_dependence" title="Amphetamine dependence">Amphetamine dependence</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Hallucinogen" title="Hallucinogen">Hallucinogen</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>SID
<ul>
<li><a href="/wiki/Hallucinogen_persisting_perception_disorder" title="Hallucinogen persisting perception disorder">Hallucinogen persisting perception disorder</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Tobacco" title="Tobacco">Tobacco</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>SID
<ul>
<li><a href="/wiki/Nicotine_poisoning" title="Nicotine poisoning">Nicotine poisoning</a></li>
<li><a href="/wiki/Nicotine_withdrawal" title="Nicotine withdrawal">Nicotine withdrawal</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Solvent" title="Solvent">Volatile<br />
solvent</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Inhalant" title="Inhalant" class="mw-redirect">Inhalant abuse</a>: <a href="/wiki/Toluene_toxicity" title="Toluene toxicity">Toluene toxicity</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Multiple</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Poly_drug_use" title="Poly drug use">Poly drug use</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Psych_navs" title="Template:Psych navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Psych_navs" title="Template talk:Psych navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Psych_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of <a href="/wiki/Psychology" title="Psychology">psychology</a> and <a href="/wiki/Psychiatry" title="Psychiatry">psychiatry</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Mental_processes" title="Template:Mental processes">Mental processes</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disorders</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Mental_and_behavioral_disorders" title="Template:Mental and behavioral disorders">Mental and behavioral</a>
<ul>
<li><a href="/wiki/Template:Attention-deficit_hyperactivity_disorder" title="Template:Attention-deficit hyperactivity disorder">ADHD</a></li>
<li><a href="/wiki/Template:Obsessive%E2%80%93compulsive_disorder" title="Template:Obsessive–compulsive disorder">OCD</a></li>
<li><a href="/wiki/Template:Tourette_syndrome" title="Template:Tourette syndrome">Tourette's</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Mood_disorders" title="Template:Mood disorders">Mood</a></li>
<li>Developmental
<ul>
<li><a href="/wiki/Template:Pervasive_developmental_disorders" title="Template:Pervasive developmental disorders">pervasive</a></li>
<li><a href="/wiki/Template:Dyslexia_and_specific_developmental_disorders" title="Template:Dyslexia and specific developmental disorders">dyslexia and specific</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Psychoactive_substance_use" title="Template:Psychoactive substance use">Substance-related</a>
<ul>
<li><a href="/wiki/Template:Alcohol_and_health" title="Template:Alcohol and health">alcohol</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Emotional_and_behavioral_disorders" title="Template:Emotional and behavioral disorders">Emotional and behavioral</a></li>
<li><a href="/wiki/Template:Cognition,_perception,_emotional_state_and_behaviour_symptoms_and_signs" title="Template:Cognition, perception, emotional state and behaviour symptoms and signs">Symptoms and signs</a>
<ul>
<li><a href="/wiki/Template:Eponymous_medical_signs_for_nervous_system" title="Template:Eponymous medical signs for nervous system">eponymous</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Psychological_and_psychiatric_evaluation_and_testing" title="Template:Psychological and psychiatric evaluation and testing">Evaluation and testing</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Psychotherapy" title="Template:Psychotherapy">Psychotherapy</a>
<ul>
<li><a href="/wiki/Template:Cognitive_behavioral_therapy" title="Template:Cognitive behavioral therapy">CBT</a></li>
</ul>
</li>
<li>Drugs
<ul>
<li><a href="/wiki/Template:Antidepressants" title="Template:Antidepressants">depression</a></li>
<li><a href="/wiki/Template:Antipsychotics" title="Template:Antipsychotics">antipsychotics</a></li>
<li><a href="/wiki/Template:Anxiolytics" title="Template:Anxiolytics">anxiety</a></li>
<li><a href="/wiki/Template:Anti-dementia_drugs" title="Template:Anti-dementia drugs">dementia</a></li>
<li><a href="/wiki/Template:Hypnotics_and_sedatives" title="Template:Hypnotics and sedatives">hypnotics and sedatives</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Addiction" title="Template:Addiction"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Addiction" title="Template talk:Addiction"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Addiction&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Addiction" title="Addiction">Addiction</a>, <a href="/wiki/Substance_dependence" title="Substance dependence">dependence</a>, and other <a href="/wiki/Reinforcement" title="Reinforcement">reinforcement</a> disorders</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Addiction</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:8em;padding-left:0;padding-right:0;text-align:center;">
<div style="padding:0em 0.75em;"><a href="/wiki/Drug_addiction" title="Drug addiction" class="mw-redirect">Drug</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcoholism" title="Alcoholism">Alcoholism</a></li>
<li><a href="/wiki/Amphetamine#Addiction" title="Amphetamine">Amphetamine</a></li>
<li><a href="/wiki/Cocaine_addiction" title="Cocaine addiction" class="mw-redirect">Cocaine</a></li>
<li><a href="/wiki/Ethanol#Addiction" title="Ethanol">Ethanol</a></li>
<li><a href="/wiki/Methamphetamine#Addiction" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/Methylphenidate#Addiction" title="Methylphenidate">Methylphenidate</a></li>
<li><a href="/wiki/Nicotine_addiction" title="Nicotine addiction" class="mw-redirect">Nicotine</a></li>
<li><a href="/wiki/Opioid_addiction" title="Opioid addiction" class="mw-redirect">Opioid</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:8em;padding-left:0;padding-right:0;text-align:center;">
<div style="padding:0em 0.75em;"><a href="/wiki/Behavioral_addiction" title="Behavioral addiction">Behavioral</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Exercise_addiction" title="Exercise addiction">Exercise</a></li>
<li><a href="/wiki/Compulsive_overeating" title="Compulsive overeating" class="mw-redirect">Palatable food</a>
<ul>
<li><a href="/wiki/Sugar_addiction" title="Sugar addiction">Sugar</a></li>
</ul>
</li>
<li><a href="/wiki/Problem_gambling" title="Problem gambling">Gambling</a></li>
<li>Media
<ul>
<li><a href="/wiki/Computer_addiction" title="Computer addiction">Computer</a></li>
<li><a href="/wiki/Internet_addiction_disorder" title="Internet addiction disorder">Internet</a></li>
<li><a href="/wiki/Video_game_addiction" title="Video game addiction">Video game</a></li>
</ul>
</li>
<li>Sex-related
<ul>
<li><a href="/wiki/Internet_sex_addiction" title="Internet sex addiction">Cybersex</a></li>
<li><a href="/wiki/Sexual_addiction" title="Sexual addiction">Intercourse</a></li>
<li><a href="/wiki/Pornography_addiction" title="Pornography addiction">Pornography</a></li>
</ul>
</li>
<li><a href="/wiki/Compulsive_buying_disorder" title="Compulsive buying disorder">Shopping</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:8em;padding-left:0;padding-right:0;text-align:center;">
<div style="padding:0em 0.75em;">Cellular<br />
mechanisms</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Transcription_factor" title="Transcription factor">Transcriptional</a>
<ul>
<li><b><a href="/wiki/FOSB#.CE.94FosB" title="FOSB">ΔFosB</a></b></li>
<li><a href="/wiki/C-Fos" title="C-Fos">c-Fos</a></li>
<li><a href="/wiki/Cdk5" title="Cdk5" class="mw-redirect">Cdk5</a></li>
<li><a href="/wiki/CREB" title="CREB">CREB</a></li>
<li><a href="/wiki/GluR2" title="GluR2" class="mw-redirect">GluR2</a></li>
<li><a href="/wiki/NF-%CE%BAB" title="NF-κB">NF-κB</a></li>
</ul>
</li>
</ul>
<ul>
<li><a href="/wiki/Histone-modifying_enzymes" title="Histone-modifying enzymes">Epigenetic</a>
<ul>
<li><b><a href="/wiki/G9a" title="G9a" class="mw-redirect">G9a</a></b></li>
<li><a href="/wiki/G9a-like_protein" title="G9a-like protein" class="mw-redirect">G9a-like protein</a></li>
<li><b><a href="/wiki/HDAC1" title="HDAC1">HDAC1</a></b></li>
<li><b><a href="/wiki/HDAC2" title="HDAC2" class="mw-redirect">HDAC2</a></b></li>
<li><b><a href="/wiki/HDAC3" title="HDAC3">HDAC3</a></b></li>
<li><a href="/wiki/HDAC4" title="HDAC4">HDAC4</a></li>
<li><a href="/wiki/HDAC5" title="HDAC5" class="mw-redirect">HDAC5</a></li>
<li><a href="/wiki/HDAC9" title="HDAC9">HDAC9</a></li>
<li><a href="/wiki/HDAC10" title="HDAC10">HDAC10</a></li>
<li><a href="/wiki/SIRT1" title="SIRT1" class="mw-redirect">SIRT1</a></li>
<li><a href="/wiki/SIRT2" title="SIRT2">SIRT2</a></li>
<li>...</li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Dependence</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group" style="width:8em;padding-left:0;padding-right:0;text-align:center;">
<div style="padding:0em 0.75em;">Concepts</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Physical_dependence" title="Physical dependence">Physical dependence</a></li>
<li><a href="/wiki/Psychological_dependence" title="Psychological dependence">Psychological dependence</a></li>
<li><a href="/wiki/Drug_withdrawal" title="Drug withdrawal">Withdrawal</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:8em;padding-left:0;padding-right:0;text-align:center;">
<div style="padding:0em 0.75em;">Disorders</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcoholism" title="Alcoholism">Alcoholism</a></li>
<li><a href="/wiki/Amphetamine#Dependence_and_withdrawal" title="Amphetamine">Amphetamine</a></li>
<li><a href="/wiki/Barbiturate_dependence" title="Barbiturate dependence">Barbiturate</a></li>
<li><strong class="selflink">Benzodiazepine</strong></li>
<li><a href="/wiki/Caffeine_dependence" title="Caffeine dependence">Caffeine</a></li>
<li><a href="/wiki/Cannabis_dependence" title="Cannabis dependence">Cannabis</a></li>
<li><a href="/wiki/Cocaine_dependence" title="Cocaine dependence">Cocaine</a></li>
<li><a href="/wiki/Nicotine_dependence" title="Nicotine dependence" class="mw-redirect">Nicotine</a></li>
<li><a href="/wiki/Opioid_dependence" title="Opioid dependence" class="mw-redirect">Opioid</a></li>
<li><a href="/wiki/Amphetamine_dependence" title="Amphetamine dependence">Substituted amphetamine</a></li>
<li><a href="/wiki/Workaholic" title="Workaholic">Work</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">See also</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Addiction_recovery_groups" title="Addiction recovery groups">Addiction recovery groups</a></li>
<li><a href="/wiki/Harm_reduction" title="Harm reduction">Harm reduction</a></li>
<li><a href="/wiki/List_of_twelve-step_groups" title="List of twelve-step groups">List of twelve-step groups</a></li>
<li><a href="/wiki/NoFap" title="NoFap">NoFap</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1014
CPU time usage: 1.528 seconds
Real time usage: 1.632 seconds
Preprocessor visited node count: 8101/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 304636/2097152 bytes
Template argument size: 8608/2097152 bytes
Highest expansion depth: 16/40
Expensive parser function count: 3/500
Lua time usage: 0.647/10.000 seconds
Lua memory usage: 4.31 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00% 1340.531      1 - -total
 63.47%  850.780      1 - Template:Reflist
 35.80%  479.865     73 - Template:Cite_journal
 17.77%  238.165      8 - Template:Navbox
  7.84%  105.071      5 - Template:Navbox_subgroup
  6.47%   86.727      1 - Template:Psychoactive_substance_use
  5.86%   78.510     14 - Template:Cite_book
  5.45%   73.048      1 - Template:Infobox_disease
  4.89%   65.554      1 - Template:Lead_too_long
  4.45%   59.708      1 - Template:Infobox
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:20767273-0!*!0!!en!4!* and timestamp 20150710172259 and revision id 667301294
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Benzodiazepine_dependence&amp;oldid=667301294">https://en.wikipedia.org/w/index.php?title=Benzodiazepine_dependence&amp;oldid=667301294</a>"					</div>
				<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Pharmacology" title="Category:Pharmacology">Pharmacology</a></li><li><a href="/wiki/Category:Substance_dependence" title="Category:Substance dependence">Substance dependence</a></li><li><a href="/wiki/Category:Syndromes" title="Category:Syndromes">Syndromes</a></li><li><a href="/wiki/Category:Benzodiazepines" title="Category:Benzodiazepines">Benzodiazepines</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:CS1_Dutch-language_sources_(nl)" title="Category:CS1 Dutch-language sources (nl)">CS1 Dutch-language sources (nl)</a></li><li><a href="/wiki/Category:Pages_containing_cite_templates_with_deprecated_parameters" title="Category:Pages containing cite templates with deprecated parameters">Pages containing cite templates with deprecated parameters</a></li><li><a href="/wiki/Category:CS1_Spanish-language_sources_(es)" title="Category:CS1 Spanish-language sources (es)">CS1 Spanish-language sources (es)</a></li><li><a href="/wiki/Category:CS1_French-language_sources_(fr)" title="Category:CS1 French-language sources (fr)">CS1 French-language sources (fr)</a></li><li><a href="/wiki/Category:CS1_Japanese-language_sources_(ja)" title="Category:CS1 Japanese-language sources (ja)">CS1 Japanese-language sources (ja)</a></li><li><a href="/wiki/Category:CS1_German-language_sources_(de)" title="Category:CS1 German-language sources (de)">CS1 German-language sources (de)</a></li><li><a href="/wiki/Category:Wikipedia_introduction_cleanup_from_February_2015" title="Category:Wikipedia introduction cleanup from February 2015">Wikipedia introduction cleanup from February 2015</a></li><li><a href="/wiki/Category:All_pages_needing_cleanup" title="Category:All pages needing cleanup">All pages needing cleanup</a></li><li><a href="/wiki/Category:Articles_covered_by_WikiProject_Wikify_from_February_2015" title="Category:Articles covered by WikiProject Wikify from February 2015">Articles covered by WikiProject Wikify from February 2015</a></li><li><a href="/wiki/Category:All_articles_covered_by_WikiProject_Wikify" title="Category:All articles covered by WikiProject Wikify">All articles covered by WikiProject Wikify</a></li><li><a href="/wiki/Category:Articles_with_contributors_link" title="Category:Articles with contributors link">Articles with contributors link</a></li><li><a href="/wiki/Category:All_accuracy_disputes" title="Category:All accuracy disputes">All accuracy disputes</a></li><li><a href="/wiki/Category:Articles_with_disputed_statements_from_December_2011" title="Category:Articles with disputed statements from December 2011">Articles with disputed statements from December 2011</a></li><li><a href="/wiki/Category:Articles_with_DMOZ_links" title="Category:Articles with DMOZ links">Articles with DMOZ links</a></li><li><a href="/wiki/Category:Articles_that_use_a_Medicine_navs_subtemplate" title="Category:Articles that use a Medicine navs subtemplate">Articles that use a Medicine navs subtemplate</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Benzodiazepine+dependence&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Benzodiazepine+dependence" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Benzodiazepine_dependence"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Benzodiazepine_dependence"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Benzodiazepine_dependence" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Benzodiazepine_dependence" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Benzodiazepine_dependence" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Benzodiazepine_dependence&amp;oldid=667301294" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Benzodiazepine_dependence&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q380409" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Benzodiazepine_dependence&amp;id=667301294" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Benzodiazepine+dependence">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Benzodiazepine+dependence&amp;oldid=667301294&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Benzodiazepine_dependence&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Sch%C3%A4dlicher_Gebrauch_von_Benzodiazepinen" title="Schädlicher Gebrauch von Benzodiazepinen – German" lang="de" hreflang="de">Deutsch</a></li><li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Dependencia_de_las_benzodiazepinas" title="Dependencia de las benzodiazepinas – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D9%88%D8%A7%D8%A8%D8%B3%D8%AA%DA%AF%DB%8C_%D8%A8%D9%87_%D8%A8%D9%86%D8%B2%D9%88%D8%AF%DB%8C%D8%A7%D8%B2%D9%BE%DB%8C%D9%86%E2%80%8C%D9%87%D8%A7" title="وابستگی به بنزودیازپین‌ها – Persian" lang="fa" hreflang="fa">فارسی</a></li><li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E3%83%99%E3%83%B3%E3%82%BE%E3%82%B8%E3%82%A2%E3%82%BC%E3%83%94%E3%83%B3%E4%BE%9D%E5%AD%98%E7%97%87" title="ベンゾジアゼピン依存症 – Japanese" lang="ja" hreflang="ja">日本語</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q380409#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 17 June 2015, at 04:40.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Benzodiazepine_dependence&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_132x47.png 1.5x, //en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>if(window.jQuery)jQuery.ready();</script><script>if(window.mw){
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","site":"loading","user":"ready","user.groups":"ready"});
}</script>
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.wikimediaBadges&amp;only=styles&amp;skin=vector&amp;*" />
<script>if(window.mw){
mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.cirrusSearch.loggingSchema","mmv.bootstrap.autostart","ext.imageMetrics.loader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.wikimediaEvents.statsd","ext.navigationTiming","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.WatchlistGreenIndicators","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.visualEditor.targetLoader","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"],null,true);
}</script>
<script>if(window.mw){
document.write("\u003Cscript src=\"//en.wikipedia.org/w/load.php?debug=false\u0026amp;lang=en\u0026amp;modules=site\u0026amp;only=scripts\u0026amp;skin=vector\u0026amp;*\"\u003E\u003C/script\u003E");
}</script>
<script>if(window.mw){
mw.config.set({"wgBackendResponseTime":95,"wgHostname":"mw1065"});
}</script>
	</body>
</html>
